Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Alnylam Pharmaceuticals, Inc. (ALNY)
USD288.06
-10.70 (-3.58%)
US NASDAQ NASDAQ 100
Healthcare Biotechnology
Address
675 West Kendall Street 2142
Cambridge, MA, US
Cambridge, MA, US
CEO
Yvonne L. Greenstreet
Website
alnylam.com
IPO
2004-06-01
CIK 1178670 ISIN US02043Q1076
Also trades on
Deutsche Börse · DUL.DE (EUR)
London Stock Exchange · 0HD2.L (USD)
NASDAQ Global Select · ALNY (USD)
Description
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
News Sentiment (7d)
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Index membership
| Index | Added | Removed | Status |
|---|---|---|---|
| NASDAQ 100 | 2025-12-22 | — | Active |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD288.06
-10.70 (-3.58%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.27
Float Shares
132.51M
Free Float %
99.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.52% | -2.83% | -9.34% | -5.33% | -35.50% | -26.56% | +8.08% | +42.20% | +118.98% | +457.63% | +4,759.07% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (52 ratings, all time)
Buy
Price Targets & DCF
Current price
288.06
Low
351.00
+21.8%
Consensus
445.67
+54.7%
Median
445.50
+54.7%
High
530.00
+84.0%
Ratings Trend (MoM)
71% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 6 | 0 |
| Buy | 14 | 0 |
| Hold | 8 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 2 |
408.50
+41.8%
|
| Last Quarter | 7 |
418.00
+45.1%
|
| Last Year | 30 |
460.47
+59.9%
|
| All Time | 69 |
344.72
+19.7%
|
Quality scores
Altman Z-Score
5.73
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
3 / 10
No MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+65.2% ★ Q1'26: +96.4% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+206.9% ★ Q1'26: +443.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-5.5% Q1'26: +4.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+13.5% ★ Q1'26: +13.1% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: -92.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+5.5% Q1'26: +6.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×2.29× ★ Q1'26: 2.09× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 19 Rev. Ana. 15 EPS Ana. |
Dec 2027 19 Rev. Ana. 14 EPS Ana. |
Dec 2028 18 Rev. Ana. 16 EPS Ana. |
Dec 2029 11 Rev. Ana. 14 EPS Ana. |
Dec 2030 9 Rev. Ana. 14 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
82.76M
est: 82.30M (+0.6%)
|
66.73M
est: 85.61M (-22.1%)
|
47.17M
est: 61.15M (-22.9%)
|
50.56M
est: 81.77M (-38.2%)
|
41.10M
est: 43.50M (-5.5%)
|
47.16M
est: 42.48M (+11.0%)
|
89.91M
est: 70.82M (+27.0%)
|
74.91M
est: 70.69M (+6.0%)
|
219.75M
est: 222.13M (-1.1%)
|
492.85M
est: 475.26M (+3.7%)
|
844.29M
est: 820.81M (+2.9%)
|
1.04B
est: 1.01B (+2.4%)
|
1.83B
est: 2.34B (-22.0%)
|
2.25B
est: 2.24B (+0.2%)
|
3.71B
est: 3.75B (-1.0%)
|
5.62B
5.50B – 6.07B
+49.7% YoY
|
7.38B
6.72B – 9.08B
+31.4% YoY
|
8.80B
8.80B – 8.80B
+19.3% YoY
|
10.16B
9.45B – 11.86B
+15.4% YoY
|
11.74B
10.93B – 13.71B
+15.6% YoY
|
| EBITDA |
-49.69M
est: -50.54M (+1.7%)
|
-51.71M
est: -139.33M (+62.9%)
|
-82.71M
est: -76.80M (-7.7%)
|
-172.29M
est: -478.85M (+64.0%)
|
-276.96M
est: -253.54M (-9.2%)
|
-409.46M
est: -387.83M (-5.6%)
|
-488.19M
est: -450.44M (-8.4%)
|
-754.24M
est: -729.10M (-3.4%)
|
-868.08M
est: -822.45M (-5.5%)
|
-736.33M
est: -659.42M (-11.7%)
|
-661.56M
est: -724.59M (+8.7%)
|
-926.56M
est: -775.24M (-19.5%)
|
-258.24M
est: -819.35M (+68.5%)
|
-178.85M
est: -783.79M (+77.2%)
|
557.24M
est: -1.31B (+142.5%)
|
-1.96B
-2.12B – -1.92B
-49.7% YoY
|
-2.58B
-3.17B – -2.35B
-31.4% YoY
|
-3.08B
-3.08B – -3.08B
-19.3% YoY
|
-3.55B
-4.14B – -3.30B
-15.4% YoY
|
-4.10B
-4.79B – -3.82B
-15.6% YoY
|
| EBIT |
-57.65M
est: -52.73M (-9.3%)
|
-63.57M
est: -169.98M (+62.6%)
|
-92.94M
est: -88.19M (-5.4%)
|
-184.21M
est: -498.22M (+63.0%)
|
-296.01M
est: -276.97M (-6.9%)
|
-424.59M
est: -416.30M (-2.0%)
|
-500.09M
est: -471.56M (-6.1%)
|
-760.67M
est: -789.56M (+3.7%)
|
-885.25M
est: -929.27M (+4.7%)
|
-771.10M
est: -772.07M (+0.1%)
|
-709.12M
est: -608.72M (-16.5%)
|
-971.03M
est: -565.12M (-71.8%)
|
-312.30M
est: -898.58M (+65.2%)
|
-235.52M
est: -859.57M (+72.6%)
|
501.58M
est: -1.44B (+134.9%)
|
-2.15B
-2.33B – -2.11B
-49.7% YoY
|
-2.83B
-3.48B – -2.57B
-31.4% YoY
|
-3.37B
-3.37B – -3.37B
-19.3% YoY
|
-3.89B
-4.55B – -3.62B
-15.4% YoY
|
-4.50B
-5.26B – -4.19B
-15.6% YoY
|
| Net Income |
-57.65M
est: -55.52M (-3.8%)
|
-106.01M
est: -132.74M (+20.1%)
|
-89.23M
est: -83.91M (-6.3%)
|
-360.40M
est: -439.32M (+18.0%)
|
-290.07M
est: -271.35M (-6.9%)
|
-410.11M
est: -402.69M (-1.8%)
|
-490.87M
est: -463.06M (-6.0%)
|
-761.50M
est: -735.72M (-3.5%)
|
-886.12M
est: -878.28M (-0.9%)
|
-858.28M
est: -777.85M (-10.3%)
|
-852.82M
est: -723.17M (-17.9%)
|
-1.13B
est: -770.44M (-46.8%)
|
-440.24M
est: -72.94M (-503.6%)
|
-278.16M
est: -319.09M (+12.8%)
|
313.75M
est: 308.23M (+1.8%)
|
1.03B
851.81M – 1.13B
+232.8% YoY
|
1.52B
1.16B – 1.62B
+47.9% YoY
|
1.98B
1.15B – 2.64B
+30.7% YoY
|
2.13B
1.94B – 2.59B
+7.3% YoY
|
2.62B
2.38B – 3.19B
+22.9% YoY
|
| SGA |
38.28M
est: 36.95M (+3.6%)
|
44.61M
est: 45.20M (-1.3%)
|
27.15M
est: 27.37M (-0.8%)
|
44.53M
est: 52.55M (-15.3%)
|
60.61M
est: 30.81M (+96.7%)
|
89.35M
est: 30.08M (+197.0%)
|
199.37M
est: 50.15M (+297.5%)
|
382.36M
est: 50.06M (+663.8%)
|
479.01M
est: 157.31M (+204.5%)
|
588.42M
est: 336.58M (+74.8%)
|
620.64M
est: 527.46M (+17.7%)
|
770.66M
est: 513.33M (+50.1%)
|
795.65M
est: 1.25B (-36.5%)
|
975.53M
est: 1.20B (-18.6%)
|
1.21B
est: 2.01B (-39.6%)
|
3.00B
2.94B – 3.25B
+49.7% YoY
|
3.95B
3.59B – 4.86B
+31.4% YoY
|
4.71B
4.70B – 4.71B
+19.3% YoY
|
5.43B
5.05B – 6.34B
+15.4% YoY
|
6.28B
5.84B – 7.33B
+15.6% YoY
|
| EPS |
-1.36
est: -1.31 (-3.8%)
|
-2.11
est: -3.00 (+29.7%)
|
-1.45
est: -1.48 (+1.7%)
|
-4.85
est: -2.72 (-78.6%)
|
-3.45
est: -3.34 (-3.4%)
|
-4.79
est: -4.88 (+1.8%)
|
-5.42
est: -5.29 (-2.5%)
|
-7.57
est: -7.65 (+1.0%)
|
-8.11
est: -7.90 (-2.7%)
|
-7.46
est: -7.20 (-3.6%)
|
-7.20
est: -6.44 (-11.7%)
|
-9.30
est: -8.95 (-3.9%)
|
-3.52
est: -0.58 (-507.7%)
|
-2.18
est: -2.06 (-5.8%)
|
2.39
est: 2.46 (-3.0%)
|
7.39
6.32 – 8.40
+200.0% YoY
|
10.65
8.59 – 12.05
+44.0% YoY
|
13.30
8.55 – 19.61
+25.0% YoY
|
15.81
14.38 – 19.25
+18.8% YoY
|
19.43
17.68 – 23.67
+22.9% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-05 | HC Wainwright & Co. | Buy | Buy | Maintain |
| 2026-05-01 | RBC Capital | Outperform | Outperform | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
1.57B
OE per share TTM
11.49
Owner's Yield
4.14%
Maintenance CapEx ratio
122.07%
Maint CapEx / Avg PPE
47.7%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
178
Total invested
643.65M
Insider transactions (90d)
0
Beneficial owners (>5%)
16
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Abigail P. Johnson | 16.72M | 15.00% | — | — | 16.72M | — | IN | Delaware | 2020-02-07 | ↗ |
| 2 | FMR LLC | 16.72M | 15.00% | 4.54M | — | 16.72M | — | HC | Delaware | 2020-02-07 | ↗ |
| 3 | The Vanguard Group - 23-1945930 | 10.70M | 8.95% | — | 114.6K | 10.44M | 260.9K | IA | Pennsylvania | 2022-02-09 | ↗ |
| 4 | Baillie Gifford & Co (Scottish partnership) | 10.62M | 11.00% | — | — | — | — | IA | SCOTLAND UK | 2022-01-18 | ↗ |
| 5 | Wellington Group Holdings LLP | 10.06M | 8.66% | — | 9.75M | — | — | HC | Delaware | 2021-02-03 | ↗ |
| 6 | Wellington Investment Advisors Holdings LLP | 10.06M | 8.66% | — | 9.75M | — | — | HC | Delaware | 2021-02-03 | ↗ |
| 7 | Wellington Management Company LLP | 9.65M | 8.31% | — | 9.61M | — | — | IA | Delaware | 2021-02-03 | ↗ |
| 8 | 2 | 9.20M | 10.70% | 8.79M | — | 9.20M | — | IA | California USA | 2017-02-14 | ↗ |
| 9 | OF 4 PAGES | 8.23M | 8.30% | 7.83M | — | 8.23M | — | IA | California USA | 2018-02-09 | ↗ |
| 10 | (1) BlackRock, Inc. | 7.67M | 6.40% | 6.93M | — | 7.67M | — | HC | Delaware | 2022-02-03 | ↗ |
| 11 | Wellington Management Group LLP | 6.84M | 5.72% | — | 6.58M | — | 6.84M | HC | Massachusetts | 2022-02-04 | ↗ |
| 12 | 52-0556948 | 6.54M | 5.40% | 1.89M | — | 6.54M | — | IA | Maryland | 2022-02-14 | ↗ |
| 13 | PAGE 2 OF 4 PAGES | 4.69M | 4.60% | 4.48M | — | 4.69M | — | IA | California USA | 2019-02-14 | ↗ |
| 14 | 0 % | — | 0.00% | — | — | — | — | CO | The Republic of France | 2019-05-03 | ↗ |
| 15 | 10. | — | 0.00% | — | — | — | — | CO | Delaware | 2017-08-09 | ↗ |
| 16 | VANGUARD SPECIALIZED FUNDS - VANGUARD HEALTH CARE FUND - 23-2439149 | — | 0.00% | — | — | — | — | IV | Delaware | 2020-02-12 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
178
-709 vs prev Q
New positions
26
Closed positions
696
Increased
93
Reduced
49
Put/Call ratio
0.00
Calls held
—
Puts held
37.9K
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 311.8K +311.8K (+100.0%) | 123.97B +124.0B (+100.0%) | 0.24% +0.238 pp | 0.19% +0.187 pp | USD397.65 +0.0% | 1 qtrs NEW |
| 2 | CAPITAL WORLD INVESTORS | 16.30M -132.5K (-0.8%) | 6.48B -1.0B (-13.5%) | 12.40% -0.272 pp | 0.88% -0.142 pp | USD196.17 +102.7% | 50 qtrs — |
| 3 | FMR LLC | 15.90M -865.5K (-5.2%) | 6.32B -1.3B (-17.3%) | 12.03% -0.905 pp | 0.32% -0.075 pp | USD168.20 +136.4% | 70 qtrs — |
| 4 | VANGUARD GROUP INC | 13.55M -11.5K (-0.1%) | 5.39B -796.1M (-12.9%) | 10.35% -0.115 pp | 0.08% -0.015 pp | USD113.95 +249.0% | 84 qtrs — |
| 5 | BLACKROCK, INC. | 10.40M +497.3K (+5.0%) | 4.14B -380.1M (-8.4%) | 7.94% +0.302 pp | 0.07% -0.009 pp | USD282.29 +40.9% | 6 qtrs — |
| 6 | CAPITAL RESEARCH GLOBAL INVESTORS | 6.78M -443.1K (-6.1%) | 2.70B -597.6M (-18.1%) | 5.16% -0.412 pp | 0.50% -0.120 pp | USD234.64 +69.5% | 13 qtrs — |
| 7 | JPMORGAN CHASE & CO | 4.72M +176.2K (+3.9%) | 1.88B -195.1M (-9.4%) | 3.59% +0.087 pp | 0.12% -0.006 pp | USD336.55 +18.2% | 51 qtrs — |
| 8 | STATE STREET CORP | 3.23M +147.5K (+4.8%) | 1.28B -121.2M (-8.6%) | 2.46% +0.089 pp | 0.04% -0.006 pp | USD124.90 +218.4% | 51 qtrs — |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 2.65M +151.5K (+6.1%) | 1.06B -79.5M (-7.0%) | 2.02% +0.096 pp | 0.07% -0.007 pp | USD167.43 +137.5% | 78 qtrs — |
| 10 | BAILLIE GIFFORD & CO | 2.60M -188.4K (-6.8%) | 1.03B -237.7M (-18.7%) | 1.98% -0.172 pp | 0.86% -0.083 pp | USD97.48 +307.9% | 51 qtrs — |
| 11 | NORGES BANK | 2.25M +2.3M (+100.0%) | 895.82M +895.8M (+100.0%) | 1.71% +1.714 pp | 0.10% +0.096 pp | USD397.65 +0.0% | 1 qtrs NEW |
| 12 | INVESCO LTD. | 2.17M +684.0K (+46.2%) | 861.25M +185.5M (+27.5%) | 1.65% +0.511 pp | 0.13% +0.026 pp | USD326.06 +22.0% | 57 qtrs — |
| 13 | DODGE & COX | 1.96M -356.8K (-15.4%) | 781.15M -277.3M (-26.2%) | 1.49% -0.304 pp | 0.42% -0.150 pp | USD82.64 +381.2% | 39 qtrs — |
| 14 | T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 1.75M -420.3K (-19.3%) | 697.34M -294.0M (-29.7%) | 1.33% -0.350 pp | 0.44% -0.166 pp | USD212.25 +87.3% | 14 qtrs — |
| 15 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.70M -97.5K (-5.4%) | 677.13M -143.8M (-17.5%) | 1.30% -0.089 pp | 0.07% -0.015 pp | USD131.17 +203.2% | 75 qtrs — |
| 16 | WELLINGTON MANAGEMENT GROUP LLP | 1.63M -197.4K (-10.8%) | 647.74M -185.1M (-22.2%) | 1.23% -0.177 pp | 0.11% -0.032 pp | USD106.32 +274.0% | 50 qtrs — |
| 17 | ORBIS ALLAN GRAY LTD | 1.62M -332.7K (-17.1%) | 643.48M -246.2M (-27.7%) | 1.22% -0.281 pp | 2.70% -1.122 pp | USD271.75 +46.3% | 7 qtrs — |
| 18 | AMERICAN CENTURY COMPANIES INC | 1.49M -156.3K (-9.5%) | 590.58M -157.9M (-21.1%) | 1.12% -0.143 pp | 0.30% -0.084 pp | USD181.73 +118.8% | 31 qtrs — |
| 19 | TWO SIGMA ADVISERS, LP | 1.13M +240.1K (+26.9%) | 450.36M +43.4M (+10.7%) | 0.86% +0.176 pp | 0.88% +0.061 pp | USD393.72 +1.0% | 17 qtrs — |
| 20 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.13M -228.4K (-16.9%) | 448.22M -169.9M (-27.5%) | 0.85% -0.193 pp | 0.26% -0.127 pp | USD439.57 -9.5% | 4 qtrs — |
| 21 | MORGAN STANLEY | 970.2K +244.1K (+33.6%) | 385.78M +54.7M (+16.5%) | 0.74% +0.181 pp | 0.02% +0.003 pp | USD248.87 +59.8% | 51 qtrs — |
| 22 | LEGAL & GENERAL GROUP PLC | 961.5K +73.7K (+8.3%) | 382.34M -22.5M (-5.6%) | 0.73% +0.047 pp | 0.08% -0.006 pp | USD169.28 +134.9% | 44 qtrs — |
| 23 | AQR CAPITAL MANAGEMENT LLC | 920.0K +176.0K (+23.6%) | 365.82M +29.8M (+8.9%) | 0.70% +0.122 pp | 0.19% -0.024 pp | USD399.64 -0.5% | 17 qtrs — |
| 24 | NORTHERN TRUST CORP | 857.7K +24.6K (+3.0%) | 341.08M -38.8M (-10.2%) | 0.65% +0.006 pp | 0.04% -0.005 pp | USD138.98 +186.1% | 51 qtrs — |
| 25 | UBS GROUP AG | 825.8K +337.6K (+69.2%) | 328.40M +105.8M (+47.5%) | 0.63% +0.254 pp | 0.05% +0.018 pp | USD320.45 +24.1% | 45 qtrs — |
| 26 | FRANKLIN RESOURCES INC | 787.6K +73.6K (+10.3%) | 313.20M -12.4M (-3.8%) | 0.60% +0.049 pp | 0.08% -0.004 pp | USD286.65 +38.7% | 28 qtrs — |
| 27 | QUBE RESEARCH & TECHNOLOGIES LTD | 774.7K -36.6K (-4.5%) | 308.05M -61.9M (-16.7%) | 0.59% -0.040 pp | 0.31% -0.069 pp | USD456.00 -12.8% | 10 qtrs — |
| 28 | DEUTSCHE BANK AG\ | 712.0K +105.7K (+17.4%) | 283.12M +6.6M (+2.4%) | 0.54% +0.074 pp | 0.09% 0.000 pp | USD225.64 +76.2% | 50 qtrs — |
| 29 | BANK OF AMERICA CORP /DE/ | 685.2K -813.3K (-54.3%) | 272.46M -410.9M (-60.1%) | 0.52% -0.633 pp | 0.02% -0.027 pp | USD283.57 +40.2% | 52 qtrs — |
| 30 | UBS ASSET MANAGEMENT AMERICAS INC | 652.4K -56.2K (-7.9%) | 259.41M -63.7M (-19.7%) | 0.50% -0.050 pp | 0.05% -0.015 pp | USD160.16 +148.3% | 56 qtrs — |
| 31 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 647.8K +29.1K (+4.7%) | 257.61M -24.5M (-8.7%) | 0.49% +0.016 pp | 0.04% -0.005 pp | USD178.03 +123.4% | 72 qtrs — |
| 32 | FEDERATED HERMES, INC. | 628.1K +78.0K (+14.2%) | 249.75M -1.1M (-0.4%) | 0.48% +0.054 pp | 0.42% -0.026 pp | USD342.32 +16.2% | 13 qtrs — |
| 33 | TWO SIGMA INVESTMENTS, LP | 616.1K +20.2K (+3.4%) | 245.00M -26.7M (-9.8%) | 0.47% +0.011 pp | 0.35% -0.059 pp | USD355.16 +12.0% | 16 qtrs — |
| 34 | AMUNDI | 608.9K +224.6K (+58.5%) | 242.12M +68.4M (+39.4%) | 0.46% +0.168 pp | 0.07% +0.010 pp | USD257.49 +54.4% | 19 qtrs — |
| 35 | CLEARBRIDGE INVESTMENTS, LLC | 597.0K -25.4K (-4.1%) | 237.40M -46.4M (-16.4%) | 0.45% -0.026 pp | 0.19% -0.024 pp | USD339.03 +17.3% | 4 qtrs — |
| 36 | ROYAL BANK OF CANADA | 591.5K +154.7K (+35.4%) | 235.21M +36.0M (+18.1%) | 0.45% +0.115 pp | 0.04% +0.006 pp | USD273.47 +45.4% | 51 qtrs — |
| 37 | NUVEEN, LLC | 565.8K -22.0K (-3.7%) | 224.99M -43.1M (-16.1%) | 0.43% -0.021 pp | 0.06% -0.012 pp | USD270.02 +47.3% | 4 qtrs — |
| 38 | MARSHALL WACE, LLP | 549.9K +41.6K (+8.2%) | 218.68M -13.1M (-5.7%) | 0.42% +0.028 pp | 0.20% -0.036 pp | USD358.74 +10.8% | 6 qtrs — |
| 39 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 523.9K -277.3K (-34.6%) | 208.33M -157.0M (-43.0%) | 0.40% -0.218 pp | 0.02% -0.018 pp | USD390.41 +1.9% | 51 qtrs — |
| 40 | BANK OF NEW YORK MELLON CORP | 504.1K +84.4K (+20.1%) | 200.47M +9.0M (+4.7%) | 0.38% +0.060 pp | 0.04% -0.002 pp | USD177.80 +123.7% | 66 qtrs — |
| 41 | — | 198.8K +198.8K (+100.0%) | 198.83M +198.8M (+100.0%) | 0.15% +0.152 pp | 0.12% +0.115 pp | USD397.65 +0.0% | 1 qtrs NEW |
| 42 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 495.3K +138.8K (+38.9%) | 196.96M +34.4M (+21.1%) | 0.38% +0.102 pp | 0.06% +0.013 pp | USD439.65 -9.6% | 2 qtrs — |
| 43 | LOOMIS SAYLES & CO L P | 488.9K -11.8K (-2.4%) | 194.41M -33.9M (-14.8%) | 0.37% -0.014 pp | 0.23% -0.037 pp | USD177.57 +123.9% | 19 qtrs — |
| 44 | BELLEVUE GROUP AG | 445.9K -621.0 (-0.1%) | 177.31M -26.3M (-12.9%) | 0.34% -0.004 pp | 3.36% -0.871 pp | USD81.93 +385.4% | 40 qtrs — |
| 45 | D. E. SHAW & CO., INC. | 444.5K +245.1K (+122.9%) | 176.75M +85.8M (+94.4%) | 0.34% +0.182 pp | 0.10% +0.046 pp | USD368.00 +8.1% | 56 qtrs — |
| 46 | 1832 ASSET MANAGEMENT L.P. | 440.1K -19.2K (-4.2%) | 175.02M -34.4M (-16.4%) | 0.33% -0.021 pp | 0.13% -0.032 pp | USD375.25 +6.0% | 4 qtrs — |
| 47 | JACOBS LEVY EQUITY MANAGEMENT, INC | 401.4K -9.0K (-2.2%) | 159.61M -27.5M (-14.7%) | 0.30% -0.013 pp | 0.62% -0.127 pp | USD447.99 -11.2% | 4 qtrs — |
| 48 | BNP PARIBAS ARBITRAGE, SNC | 389.4K +236.4K (+154.5%) | 154.86M +85.1M (+121.9%) | 0.30% +0.179 pp | 0.07% +0.033 pp | USD363.44 +9.4% | 51 qtrs — |
| 49 | RAYMOND JAMES FINANCIAL INC | 388.7K +11.4K (+3.0%) | 154.43M -17.6M (-10.2%) | 0.29% +0.003 pp | 0.05% -0.007 pp | USD301.08 +32.1% | 5 qtrs — |
| 50 | GOLDMAN SACHS GROUP INC | 375.3K -163.0K (-30.3%) | 149.25M -96.2M (-39.2%) | 0.29% -0.130 pp | 0.02% -0.012 pp | USD233.54 +70.3% | 73 qtrs — |
| 51 | WELLS FARGO & COMPANY/MN | 370.0K +350.0K (+1,750.0%) | 147.13M +138.0M (+1,513.3%) | 0.28% +0.267 pp | 0.03% +0.025 pp | USD388.87 +2.3% | 5 qtrs — |
| 52 | SWISS NATIONAL BANK | 359.2K -16.6K (-4.4%) | 142.84M -28.5M (-16.6%) | 0.27% -0.017 pp | 0.09% -0.014 pp | USD131.73 +201.9% | 51 qtrs — |
| 53 | SQUAREPOINT OPS LLC | 351.0K +205.4K (+141.1%) | 139.56M +73.2M (+110.3%) | 0.27% +0.155 pp | 0.15% +0.082 pp | USD420.17 -5.4% | 16 qtrs — |
| 54 | KBC GROUP NV | 348.2K +74.8K (+27.4%) | 138.46M +13.8M (+11.1%) | 0.26% +0.054 pp | 0.32% +0.017 pp | USD365.44 +8.8% | 43 qtrs — |
| 55 | WORLDQUANT MILLENNIUM ADVISORS LLC | 343.4K +122.8K (+55.7%) | 136.57M +36.0M (+35.7%) | 0.26% +0.092 pp | 0.53% +0.095 pp | USD360.57 +10.3% | 14 qtrs — |
| 56 | SUMITOMO MITSUI TRUST HOLDINGS, INC. | 327.8K +13.3K (+4.2%) | 130.33M -13.1M (-9.1%) | 0.25% +0.007 pp | 0.08% -0.006 pp | USD152.25 +161.2% | 33 qtrs — |
| 57 | GILDER GAGNON HOWE & CO LLC | 319.3K -10.0K (-3.0%) | 126.97M -23.2M (-15.4%) | 0.24% -0.010 pp | 1.34% -0.190 pp | USD52.19 +661.9% | 51 qtrs — |
| 58 | PICTET ASSET MANAGEMENT HOLDING SA | 316.1K -71.5K (-18.4%) | 125.78M -50.2M (-28.5%) | 0.24% -0.058 pp | 0.12% -0.048 pp | USD186.41 +113.3% | 10 qtrs — |
| 59 | JANE STREET GROUP, LLC | 311.3K -647.5K (-67.5%) | 123.78M -313.4M (-71.7%) | 0.24% -0.503 pp | 0.02% -0.048 pp | USD449.45 -11.5% | 37 qtrs — |
| 60 | DIMENSIONAL FUND ADVISORS LP | 301.9K +59.9K (+24.8%) | 120.03M +9.7M (+8.8%) | 0.23% +0.043 pp | 0.03% +0.002 pp | USD196.43 +102.4% | 51 qtrs — |
| 61 | ORBIMED ADVISORS LLC | 288.8K -12.8K (-4.2%) | 114.84M -22.7M (-16.5%) | 0.22% -0.012 pp | 2.35% -0.888 pp | USD240.13 +65.6% | 9 qtrs — |
| 62 | ALLSPRING GLOBAL INVESTMENTS HOLDINGS, LLC | 278.7K -32.1K (-10.3%) | 111.51M -31.7M (-22.1%) | 0.21% -0.027 pp | 0.18% -0.049 pp | USD277.44 +43.3% | 17 qtrs — |
| 63 | JENNISON ASSOCIATES LLC | 277.8K -27.1K (-8.9%) | 110.45M -28.6M (-20.5%) | 0.21% -0.024 pp | 0.07% -0.015 pp | USD250.79 +58.6% | 5 qtrs — |
| 64 | LOS ANGELES CAPITAL MANAGEMENT LLC | 240.1K +80.7K (+50.6%) | 107.92M +35.2M (+48.5%) | 0.18% +0.060 pp | 0.37% +0.121 pp | USD385.38 +3.2% | 14 qtrs — |
| 65 | CONGRESS ASSET MANAGEMENT CO /MA | 269.2K +150.4K (+126.6%) | 107.06M +52.9M (+97.6%) | 0.21% +0.114 pp | 0.75% +0.393 pp | USD423.40 -6.1% | 2 qtrs — |
| 66 | TD ASSET MANAGEMENT INC | 269.1K -43.4K (-13.9%) | 107.01M -35.5M (-24.9%) | 0.20% -0.036 pp | 0.09% -0.030 pp | USD156.33 +154.4% | 51 qtrs — |
| 67 | CANADA PENSION PLAN INVESTMENT BOARD | 258.7K +122.4K (+89.8%) | 102.88M +40.7M (+65.5%) | 0.20% +0.092 pp | 0.07% +0.025 pp | USD394.37 +0.8% | 44 qtrs — |
| 68 | FIRST TRUST ADVISORS LP | 257.0K +46.6K (+22.1%) | 102.18M +6.2M (+6.5%) | 0.19% +0.032 pp | 0.07% +0.003 pp | USD253.04 +57.1% | 45 qtrs — |
| 69 | ROYAL LONDON ASSET MANAGEMENT LTD | 253.1K -4.2K (-1.6%) | 100.63M -16.7M (-14.2%) | 0.19% -0.006 pp | 0.21% -0.041 pp | USD176.17 +125.7% | 31 qtrs — |
| 70 | POLAR CAPITAL HOLDINGS PLC | 240.6K -10.9K (-4.3%) | 95.68M -19.0M (-16.6%) | 0.18% -0.010 pp | 0.37% -0.182 pp | USD223.92 +77.6% | 21 qtrs — |
| 71 | CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 237.0K +7.4K (+3.2%) | 94.25M -10.5M (-10.0%) | 0.18% +0.003 pp | 0.05% -0.009 pp | USD169.26 +134.9% | 58 qtrs — |
| 72 | CANDRIAM S.C.A. | 224.3K +11.9K (+5.6%) | 89.21M -7.7M (-7.9%) | 0.17% +0.006 pp | 0.44% -0.063 pp | USD165.71 +140.0% | 45 qtrs — |
| 73 | BARCLAYS PLC | 222.6K +117.4K (+111.6%) | 88.50M +59.6M (+205.9%) | 0.17% +0.089 pp | 0.02% +0.014 pp | USD300.78 +32.2% | 51 qtrs — |
| 74 | VICTORY CAPITAL MANAGEMENT INC | 220.9K +40.5K (+22.5%) | 87.83M +5.6M (+6.8%) | 0.17% +0.028 pp | 0.05% +0.002 pp | USD324.55 +22.5% | 26 qtrs — |
| 75 | FENGHE FUND MANAGEMENT PTE. LTD. | 218.7K +218.7K (+100.0%) | 86.97M +87.0M (+100.0%) | 0.17% +0.166 pp | 4.90% +4.896 pp | USD397.65 +0.0% | 1 qtrs NEW |
| 76 | PROSHARE ADVISORS LLC | 211.1K +206.4K (+4,457.9%) | 83.93M +81.8M (+3,874.7%) | 0.16% +0.157 pp | 0.15% +0.144 pp | USD392.35 +1.4% | 54 qtrs — |
| 77 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 201.8K -2.0K (-1.0%) | 80.25M -12.7M (-13.6%) | 0.15% -0.005 pp | 0.08% -0.015 pp | USD95.49 +316.4% | 52 qtrs — |
| 78 | CIBC PRIVATE WEALTH GROUP, LLC | 200.4K -13.8K (-6.4%) | 79.70M -18.0M (-18.4%) | 0.15% -0.013 pp | 0.13% -0.033 pp | USD183.01 +117.3% | 20 qtrs — |
| 79 | HUDSON BAY CAPITAL MANAGEMENT LP | 200.0K +200.0K (+100.0%) | 79.53M +79.5M (+100.0%) | 0.15% +0.153 pp | 0.26% +0.262 pp | USD397.65 +0.0% | 1 qtrs NEW |
| 80 | VOYA INVESTMENT MANAGEMENT LLC | 198.6K -174.7K (-46.8%) | 78.98M -91.3M (-53.6%) | 0.15% -0.137 pp | 0.08% -0.092 pp | USD355.34 +11.9% | 51 qtrs — |
| 81 | RHUMBLINE ADVISERS | 195.3K -1.2K (-0.6%) | 77.65M -12.0M (-13.3%) | 0.15% -0.003 pp | 0.06% -0.009 pp | USD149.61 +165.8% | 51 qtrs — |
| 82 | KOREA INVESTMENT CORP | 189.8K -7.1K (-3.6%) | 75.46M -14.3M (-16.0%) | 0.14% -0.008 pp | 0.15% -0.036 pp | USD325.25 +22.3% | 24 qtrs — |
| 83 | AMERIPRISE FINANCIAL INC | 181.1K -44.7K (-19.8%) | 72.03M -31.0M (-30.1%) | 0.14% -0.037 pp | 0.02% -0.007 pp | USD284.62 +39.7% | 34 qtrs — |
| 84 | CITIGROUP INC | 172.6K +111.7K (+183.5%) | 68.62M +40.9M (+147.2%) | 0.13% +0.084 pp | 0.03% +0.018 pp | USD350.06 +13.6% | 61 qtrs — |
| 85 | NATIONAL PENSION SERVICE | 168.1K -9.1K (-5.1%) | 66.86M -14.0M (-17.3%) | 0.13% -0.009 pp | 0.05% -0.013 pp | USD170.09 +133.8% | 23 qtrs — |
| 86 | RUSSELL INVESTMENTS GROUP, LTD. | 165.7K -30.2K (-15.4%) | 65.90M -23.3M (-26.1%) | 0.13% -0.026 pp | 0.07% -0.030 pp | USD344.23 +15.5% | 37 qtrs — |
| 87 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 160.6K -196.2K (-55.0%) | 63.85M -98.9M (-60.8%) | 0.12% -0.153 pp | 0.22% -0.322 pp | USD452.00 -12.0% | 7 qtrs — |
| 88 | SCS CAPITAL MANAGEMENT LLC | 149.6K -1.1K (-0.7%) | 59.49M -9.2M (-13.4%) | 0.11% -0.002 pp | 0.63% -0.118 pp | USD270.02 +47.3% | 4 qtrs — |
| 89 | ROBECO INSTITUTIONAL ASSET MANAGEMENT B.V. | 144.7K +31.6K (+28.0%) | 57.55M +6.0M (+11.6%) | 0.11% +0.023 pp | 0.08% +0.007 pp | USD295.78 +34.4% | 24 qtrs — |
| 90 | MAN GROUP PLC | 144.2K +72.5K (+101.2%) | 57.35M +24.7M (+75.5%) | 0.11% +0.054 pp | 0.10% +0.041 pp | USD411.30 -3.3% | 18 qtrs — |
| 91 | 683 CAPITAL MANAGEMENT, LLC | 141.1K +5.4K (+4.0%) | 56.11M -5.8M (-9.3%) | 0.11% +0.003 pp | 2.44% -0.792 pp | USD290.92 +36.7% | 10 qtrs — |
| 92 | MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD. | 138.8K +18.0K (+14.9%) | 55.54M +462.7K (+0.8%) | 0.11% +0.012 pp | 0.04% -0.002 pp | USD240.09 +65.6% | 43 qtrs — |
| 93 | JANUS HENDERSON GROUP PLC | 136.4K +570.0 (+0.4%) | 54.25M -7.7M (-12.4%) | 0.10% -0.002 pp | 0.02% -0.004 pp | USD194.95 +104.0% | 43 qtrs — |
| 94 | HANDELSBANKEN FONDER AB | 136.2K -19.2K (-12.3%) | 54.15M -16.7M (-23.6%) | 0.10% -0.016 pp | 0.16% -0.061 pp | USD256.33 +55.1% | 23 qtrs — |
| 95 | ABRDN PLC | 132.8K -24.6K (-15.6%) | 52.83M -18.9M (-26.3%) | 0.10% -0.020 pp | 0.08% -0.032 pp | USD199.37 +99.5% | 31 qtrs — |
| 96 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 124.6K +14.1K (+12.7%) | 49.40M -1.0M (-2.0%) | 0.09% +0.010 pp | 0.08% -0.004 pp | USD253.66 +56.8% | 5 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.13
Bearish
Ratio by volume
3.00
Bullish
Buys
29
Sells
232
Shares acquired
300.3K
Shares disposed
83.7K
Cash buys
—
Cash sales
228.00
Net activity
+216,611
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-06 | McLaughlin Melissa | Officer | S-Sale | D | Common Stock | 56 | 320.14 | 17.9K | 11,673 | D | ↗ |
| 2026-04-02 | McLaughlin Melissa | Officer | S-Sale | D | Common Stock | 265 | 316.61 | 83.9K | 13,088 | D | ↗ |
| 2026-03-25 | McLaughlin Melissa | Officer | — | — | Common Stock | 0 | 0.00 | — | 13,353 | D | ↗ |
| 2026-03-05 | Garg Pushkal | Officer | S-Sale | D | Common Stock | 654 | 322.33 | 210.8K | 20,443 | D | ↗ |
| 2026-03-05 | Fitzgerald Kevin Joseph | Officer | S-Sale | D | Common Stock | 153 | 326.24 | 49.9K | 20,569 | D | ↗ |
| 2026-03-04 | Tanguler Tolga | Officer | S-Sale | D | Common Stock | 208 | 325.67 | 67.7K | 34,297 | D | ↗ |
| 2026-03-04 | Poulton Jeffrey V. | Officer | S-Sale | D | Common Stock | 223 | 325.67 | 72.6K | 61,805 | D | ↗ |
| 2026-03-04 | Greenstreet Yvonne | Director / Officer | S-Sale | D | Common Stock | 129 | 320.01 | 41.3K | 98,364 | D | ↗ |
| 2026-03-04 | Garg Pushkal | Officer | S-Sale | D | Common Stock | 106 | 319.03 | 33.8K | 23,300 | D | ↗ |
| 2026-03-04 | Fitzgerald Kevin Joseph | Officer | S-Sale | D | Common Stock | 57 | 325.67 | 18.6K | 21,227 | D | ↗ |
| 2026-03-03 | Garg Pushkal | Officer | S-Sale | D | Common Stock | 640 | 320.48 | 205.1K | 23,869 | D | ↗ |
| 2026-03-03 | Fitzgerald Kevin Joseph | Officer | S-Sale | D | Common Stock | 359 | 321.58 | 115.4K | 21,860 | D | ↗ |
| 2026-03-02 | Tanguler Tolga | Officer | S-Sale | D | Common Stock | 100 | 328.71 | 32.9K | 36,988 | D | ↗ |
| 2026-03-02 | SUPRAN BRYAN | Officer | A-Award | A | Stock Option (right to buy) | 3,381 | 325.07 | 1.10M | 3,381 | D | ↗ |
| 2026-03-02 | Poulton Jeffrey V. | Officer | S-Sale | D | Common Stock | 234 | 329.71 | 77.2K | 64,567 | D | ↗ |
| 2026-03-02 | Greenstreet Yvonne | Director / Officer | S-Sale | D | Common Stock | 1,669 | 326.81 | 545.4K | 102,078 | D | ↗ |
| 2026-03-02 | Garg Pushkal | Officer | S-Sale | D | Common Stock | 50 | 323.62 | 16.2K | 26,848 | D | ↗ |
| 2026-03-02 | Fitzgerald Kevin Joseph | Officer | S-Sale | D | Common Stock | 94 | 331.93 | 31.2K | 23,549 | D | ↗ |
| 2026-02-27 | Tanguler Tolga | Officer | M-Exempt | D | Restricted Stock Units | 1,666 | 0.00 | — | 0 | D | ↗ |
| 2026-02-27 | Poulton Jeffrey V. | Officer | M-Exempt | A | Common Stock | 1,908 | 0.00 | — | 61,710 | D | ↗ |
| 2026-02-27 | Greenstreet Yvonne | Director / Officer | M-Exempt | D | Restricted Stock Units | 5,921 | 0.00 | — | 0 | D | ↗ |
| 2026-02-27 | Garg Pushkal | Officer | M-Exempt | A | Common Stock | 1,908 | 0.00 | — | 26,756 | D | ↗ |
| 2026-02-23 | Fitzgerald Kevin Joseph | Officer | A-Award | A | Common Stock | 158 | 0.00 | — | 21,422 | D | ↗ |
| 2026-02-17 | Fitzgerald Kevin Joseph | Officer | S-Sale | D | Common Stock | 2,041 | 331.96 | 677.5K | 21,264 | D | ↗ |
| 2026-02-13 | Tanguler Tolga | Officer | S-Sale | D | Common Stock | 1,959 | 310.08 | 607.4K | 31,769 | D | ↗ |
| 2026-02-13 | Poulton Jeffrey V. | Officer | S-Sale | D | Common Stock | 2,242 | 310.08 | 695.2K | 59,802 | D | ↗ |
| 2026-02-13 | Greenstreet Yvonne | Director / Officer | S-Sale | D | Common Stock | 6,958 | 310.08 | 2.16M | 85,662 | D | ↗ |
| 2026-02-13 | Garg Pushkal | Officer | S-Sale | D | Common Stock | 2,242 | 310.08 | 695.2K | 24,848 | D | ↗ |
| 2026-02-13 | Fitzgerald Kevin Joseph | Officer | S-Sale | D | Common Stock | 1,959 | 310.08 | 607.4K | 23,305 | D | ↗ |
| 2026-02-12 | Tanguler Tolga | Officer | A-Award | A | Common Stock | 4,000 | 0.00 | — | 33,728 | D | ↗ |
| 2026-02-12 | Poulton Jeffrey V. | Officer | A-Award | A | Common Stock | 4,579 | 0.00 | — | 62,044 | D | ↗ |
| 2026-02-12 | Greenstreet Yvonne | Director / Officer | A-Award | A | Common Stock | 14,209 | 0.00 | — | 92,620 | D | ↗ |
| 2026-02-12 | Garg Pushkal | Officer | A-Award | A | Common Stock | 4,579 | 0.00 | — | 27,090 | D | ↗ |
| 2026-02-12 | Fitzgerald Kevin Joseph | Officer | A-Award | A | Common Stock | 4,000 | 0.00 | — | 25,264 | D | ↗ |
| 2026-01-13 | Fitzgerald Kevin Joseph | Officer | S-Sale | D | Common Stock | 122 | 374.33 | 45.7K | 21,264 | D | ↗ |
| 2026-01-12 | Tanguler Tolga | Officer | S-Sale | D | Common Stock | 220 | 365.56 | 80.4K | 30,020 | D | ↗ |
| 2026-01-12 | Poulton Jeffrey V. | Officer | S-Sale | D | Common Stock | 27 | 377.82 | 10.2K | 57,465 | D | ↗ |
| 2026-01-12 | Greenstreet Yvonne | Director / Officer | S-Sale | D | Common Stock | 537 | 359.14 | 192.9K | 85,287 | D | ↗ |
| 2026-01-12 | Garg Pushkal | Officer | S-Sale | D | Common Stock | 15 | 377.82 | 5.7K | 22,511 | D | ↗ |
| 2026-01-12 | Fitzgerald Kevin Joseph | Officer | S-Sale | D | Common Stock | 39 | 353.95 | 13.8K | 25,025 | D | ↗ |
| 2026-01-11 | Tanguler Tolga | Officer | A-Award | A | Common Stock | 3,800 | 0.00 | — | 31,238 | D | ↗ |
| 2026-01-11 | Poulton Jeffrey V. | Officer | A-Award | A | Common Stock | 6,193 | 0.00 | — | 60,245 | D | ↗ |
| 2026-01-11 | Greenstreet Yvonne | Director / Officer | A-Award | A | Common Stock | 19,003 | 0.00 | — | 87,988 | D | ↗ |
| 2026-01-11 | Garg Pushkal | Officer | A-Award | A | Common Stock | 3,800 | 0.00 | — | 24,021 | D | ↗ |
| 2026-01-11 | Fitzgerald Kevin Joseph | Officer | A-Award | A | Common Stock | 3,800 | 0.00 | — | 25,064 | D | ↗ |
| 2026-01-05 | Arbuckle Stuart A | Director | A-Award | A | Stock Option (right to buy) | 3,279 | 397.83 | 1.30M | 3,279 | D | ↗ |
| 2025-11-26 | Greenstreet Yvonne | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 839 | 119.13 | 100.0K | 0 | D | ↗ |
| 2025-11-17 | Fitzgerald Kevin Joseph | Officer | S-Sale | D | Common Stock | 262 | 457.39 | 119.8K | 24,005 | D | ↗ |
| 2025-11-13 | Greenstreet Yvonne | Director / Officer | S-Sale | D | Common Stock | 1,599 | 452.85 | 724.1K | 66,746 | D | ↗ |
| 2025-11-12 | Greenstreet Yvonne | Director / Officer | S-Sale | D | Common Stock | 430 | 458.42 | 197.1K | 65,409 | D | ↗ |
| 2025-10-03 | Garg Pushkal | Officer | S-Sale | D | Common Stock | 215 | 454.37 | 97.7K | 20,221 | D | ↗ |
| 2025-10-02 | Tanguler Tolga | Officer | S-Sale | D | Common Stock | 157 | 453.77 | 71.2K | 27,661 | D | ↗ |
| 2025-10-02 | Poulton Jeffrey V. | Officer | S-Sale | D | Common Stock | 150 | 446.53 | 67.0K | 57,723 | D | ↗ |
| 2025-10-02 | Greenstreet Yvonne | Director / Officer | S-Sale | D | Common Stock | 548 | 448.77 | 245.9K | 73,264 | D | ↗ |
| 2025-10-02 | Garg Pushkal | Officer | S-Sale | D | Common Stock | 249 | 449.79 | 112.0K | 25,580 | D | ↗ |
| 2025-10-02 | Fitzgerald Kevin Joseph | Officer | S-Sale | D | Common Stock | 150 | 448.77 | 67.3K | 27,379 | D | ↗ |
| 2025-10-01 | Tanguler Tolga | Officer | A-Award | A | Common Stock | 2,851 | 0.00 | — | 28,843 | D | ↗ |
| 2025-10-01 | SUPRAN BRYAN | Officer | A-Award | A | Common Stock | 13,026 | 0.00 | — | 13,026 | D | ↗ |
| 2025-10-01 | Poulton Jeffrey V. | Officer | A-Award | A | Common Stock | 4,644 | 0.00 | — | 57,873 | D | ↗ |
| 2025-10-01 | Greenstreet Yvonne | Director / Officer | A-Award | A | Common Stock | 3,860 | 0.00 | — | 60,081 | D | ↗ |
| 2025-10-01 | Garg Pushkal | Officer | A-Award | A | Common Stock | 3,108 | 0.00 | — | 23,329 | D | ↗ |
| 2025-10-01 | Fitzgerald Kevin Joseph | Officer | A-Award | A | Common Stock | 2,102 | 0.00 | — | 24,821 | D | ↗ |
| 2025-09-15 | SUPRAN BRYAN | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-09-09 | Reitan Colleen F | Director | S-Sale | D | Common Stock | 222 | 471.25 | 104.6K | 8,403 | D | ↗ |
| 2025-08-29 | Tanguler Tolga | Officer | S-Sale | D | Common Stock | 266 | 451.52 | 120.1K | 26,136 | D | ↗ |
| 2025-08-19 | Garg Pushkal | Officer | S-Sale | D | Common Stock | 276 | 455.41 | 125.7K | 21,400 | D | ↗ |
| 2025-08-18 | Tanguler Tolga | Officer | S-Sale | D | Common Stock | 90 | 449.92 | 40.5K | 30,733 | D | ↗ |
| 2025-08-18 | Poulton Jeffrey V. | Officer | S-Sale | D | Common Stock | 886 | 454.04 | 402.3K | 50,532 | D | ↗ |
| 2025-08-18 | Greenstreet Yvonne | Director / Officer | S-Sale | D | Common Stock | 60 | 455.82 | 27.3K | 56,221 | D | ↗ |
| 2025-08-18 | Garg Pushkal | Officer | S-Sale | D | Common Stock | 39 | 447.98 | 17.5K | 23,033 | D | ↗ |
| 2025-08-18 | Fitzgerald Kevin Joseph | Officer | S-Sale | D | Common Stock | 543 | 454.04 | 246.5K | 22,972 | D | ↗ |
| 2025-08-18 | BONNEY MICHAEL W | Director | M-Exempt | D | Stock Option (right to buy) | 11,250 | 70.20 | 789.8K | 0 | D | ↗ |
| 2025-08-15 | Tanguler Tolga | Officer | A-Award | A | Common Stock | 2,851 | 0.00 | — | 30,862 | D | ↗ |
| 2025-08-15 | Poulton Jeffrey V. | Officer | A-Award | A | Common Stock | 4,644 | 0.00 | — | 52,395 | D | ↗ |
| 2025-08-15 | Greenstreet Yvonne | Director / Officer | A-Award | A | Common Stock | 14,252 | 0.00 | — | 63,200 | D | ↗ |
| 2025-08-15 | Garg Pushkal | Officer | A-Award | A | Common Stock | 2,851 | 0.00 | — | 23,072 | D | ↗ |
| 2025-08-15 | Fitzgerald Kevin Joseph | Officer | A-Award | A | Common Stock | 2,851 | 0.00 | — | 24,115 | D | ↗ |
| 2025-08-14 | Ausiello Dennis A | Director | M-Exempt | A | Common Stock | 9,000 | 72.01 | 648.1K | 9,911 | D | ↗ |
| 2025-07-01 | Fitzgerald Kevin Joseph | Officer | A-Award | A | Common Stock | 7,763 | 0.00 | — | 21,264 | D | ↗ |
| 2025-06-02 | Greenstreet Yvonne | Director / Officer | S-Sale | D | Common Stock | 19,297 | 306.00 | 5.90M | 48,948 | D | ↗ |
| 2025-05-30 | Greenstreet Yvonne | Director / Officer | S-Sale | D | Common Stock | 25,469 | 304.00 | 7.74M | 55,119 | D | ↗ |
| 2025-05-16 | Greenstreet Yvonne | Director / Officer | G-Gift | D | Common Stock | 8,376 | 0.00 | — | 48,948 | D | ↗ |
| 2025-05-15 | BONNEY MICHAEL W | Director | S-Sale | D | Common Stock | 1,263 | 277.16 | 350.1K | 22,994 | D | ↗ |
| 2025-05-08 | Sigal Charles Elliott | Director | A-Award | A | Stock Option (right to buy) | 1,558 | 258.35 | 402.5K | 1,558 | D | ↗ |
| 2025-05-08 | SCHULMAN AMY W | Director | A-Award | A | Stock Option (right to buy) | 1,558 | 258.35 | 402.5K | 1,558 | D | ↗ |
| 2025-05-08 | Reitan Colleen F | Director | A-Award | A | Stock Option (right to buy) | 1,558 | 258.35 | 402.5K | 1,558 | D | ↗ |
| 2025-05-08 | PYOTT DAVID E I | Director | A-Award | A | Stock Option (right to buy) | 1,558 | 258.35 | 402.5K | 1,558 | D | ↗ |
| 2025-05-08 | KELLOGG PETER N | Director | A-Award | A | Common Stock | 775 | 0.00 | — | 775 | D | ↗ |
| 2025-05-08 | HAMBURG MARGARET A | Director | A-Award | A | Stock Option (right to buy) | 1,558 | 258.35 | 402.5K | 1,558 | D | ↗ |
| 2025-05-08 | Bertozzi Carolyn R | Director | A-Award | A | Common Stock | 775 | 0.00 | — | 775 | D | ↗ |
| 2025-05-08 | BRANDICOURT OLIVIER | Director | A-Award | A | Common Stock | 775 | 0.00 | — | 775 | D | ↗ |
| 2025-05-08 | BONNEY MICHAEL W | Director | A-Award | A | Stock Option (right to buy) | 1,558 | 258.35 | 402.5K | 1,558 | D | ↗ |
| 2025-05-08 | Ausiello Dennis A | Director | A-Award | A | Stock Option (right to buy) | 1,558 | 258.35 | 402.5K | 1,558 | D | ↗ |
| 2025-05-02 | Greenstreet Yvonne | Director / Officer | G-Gift | D | Common Stock | 41,311 | 0.00 | — | 57,324 | D | ↗ |
| 2025-04-16 | Reitan Colleen F | Director | S-Sale | D | Common Stock | 36 | 232.86 | 8.4K | 0 | D | ↗ |
| 2025-03-24 | PYOTT DAVID E I | Director | S-Sale | D | Common Stock | 7,440 | 299.00 | 2.22M | 136 | D | ↗ |
| 2025-03-24 | Garg Pushkal | Officer | M-Exempt | A | Common Stock | 5,445 | 42.22 | 229.9K | 25,666 | D | ↗ |
| 2025-03-21 | Garg Pushkal | Officer | S-Sale | D | Common Stock | 4,321 | 285.00 | 1.23M | 20,221 | D | ↗ |
| 2025-03-13 | SCHULMAN AMY W | Director | M-Exempt | D | Stock Option (right to buy) | 2,750 | 131.21 | 360.8K | 0 | D | ↗ |
| 2025-03-04 | Garg Pushkal | Officer | S-Sale | D | Common Stock | 147 | 239.25 | 35.2K | 25,203 | D | ↗ |
| 2025-03-04 | Fitzgerald Kevin Joseph | Officer | S-Sale | D | Common Stock | 121 | 239.24 | 28.9K | 14,224 | D | ↗ |
| 2025-03-03 | Tanguler Tolga | Officer | S-Sale | D | Common Stock | 29 | 246.18 | 7.1K | 28,014 | D | ↗ |
| 2025-03-03 | Poulton Jeffrey V. | Officer | A-Award | A | Common Stock | 15,117 | 0.00 | — | 49,015 | D | ↗ |
| 2025-03-03 | Hesslein Robert W. | Officer | A-Award | A | Stock Option (right to buy) | 1,529 | 243.53 | 372.4K | 1,529 | D | ↗ |
| 2025-03-03 | Greenstreet Yvonne | Director / Officer | S-Sale | D | Common Stock | 4 | 248.36 | 993.44 | 98,635 | D | ↗ |
| 2025-03-03 | Garg Pushkal | Officer | S-Sale | D | Common Stock | 1 | 248.36 | 248.36 | 26,323 | D | ↗ |
| 2025-03-03 | Fitzgerald Kevin Joseph | Officer | S-Sale | D | Common Stock | 487 | 243.94 | 118.8K | 14,564 | D | ↗ |
| 2025-02-28 | Tanguler Tolga | Officer | S-Sale | D | Common Stock | 23 | 239.18 | 5.5K | 14,785 | D | ↗ |
| 2025-02-28 | Poulton Jeffrey V. | Officer | S-Sale | D | Common Stock | 35 | 239.18 | 8.4K | 34,583 | D | ↗ |
| 2025-02-28 | Greenstreet Yvonne | Director / Officer | S-Sale | D | Common Stock | 440 | 243.23 | 107.0K | 84,761 | D | ↗ |
| 2025-02-28 | Garg Pushkal | Officer | S-Sale | D | Common Stock | 91 | 240.32 | 21.9K | 13,674 | D | ↗ |
| 2025-02-28 | Fitzgerald Kevin Joseph | Officer | S-Sale | D | Common Stock | 37 | 244.11 | 9.0K | 12,385 | D | ↗ |
| 2025-02-27 | Tanguler Tolga | Officer | M-Exempt | A | Common Stock | 1,667 | 0.00 | — | 14,858 | D | ↗ |
| 2025-02-27 | Poulton Jeffrey V. | Officer | M-Exempt | D | Restricted Stock Units | 1,908 | 0.00 | — | 1,908 | D | ↗ |
| 2025-02-27 | Greenstreet Yvonne | Director / Officer | M-Exempt | A | Common Stock | 5,921 | 0.00 | — | 87,447 | D | ↗ |
| 2025-02-27 | Garg Pushkal | Officer | M-Exempt | D | Restricted Stock Units | 1,908 | 0.00 | — | 1,908 | D | ↗ |
| 2025-02-18 | Garg Pushkal | Officer | S-Sale | D | Common Stock | 862 | 250.11 | 215.6K | 12,675 | D | ↗ |
| 2025-02-18 | Fitzgerald Kevin Joseph | Officer | S-Sale | D | Common Stock | 1,086 | 250.21 | 271.7K | 13,235 | D | ↗ |
| 2025-02-14 | Poulton Jeffrey V. | Officer | S-Sale | D | Common Stock | 37 | 261.45 | 9.7K | 32,823 | D | ↗ |
| 2025-02-14 | Greenstreet Yvonne | Director / Officer | S-Sale | D | Common Stock | 271 | 252.50 | 68.4K | 82,468 | D | ↗ |
| 2025-02-14 | Garg Pushkal | Officer | S-Sale | D | Common Stock | 32 | 264.87 | 8.5K | 13,537 | D | ↗ |
| 2025-02-14 | Fitzgerald Kevin Joseph | Officer | S-Sale | D | Common Stock | 47 | 255.56 | 12.0K | 14,518 | D | ↗ |
| 2025-02-13 | Poulton Jeffrey V. | Officer | A-Award | A | Common Stock | 3,109 | 0.00 | — | 33,753 | D | ↗ |
| 2025-02-13 | Greenstreet Yvonne | Director / Officer | A-Award | A | Common Stock | 3,859 | 0.00 | — | 82,739 | D | ↗ |
| 2025-02-13 | Garg Pushkal | Officer | A-Award | A | Common Stock | 3,109 | 0.00 | — | 15,098 | D | ↗ |
| 2025-02-13 | Fitzgerald Kevin Joseph | Officer | A-Award | A | Common Stock | 2,103 | 0.00 | — | 14,984 | D | ↗ |
| 2025-01-27 | Garg Pushkal | Officer | M-Exempt | A | Common Stock | 25,000 | 88.95 | 2.22M | 64,581 | D | ↗ |
| 2025-01-23 | SHARP PHILLIP A | Director | M-Exempt | A | Common Stock | 11,250 | 131.21 | 1.48M | 11,250 | D | ↗ |
| 2024-12-12 | Garg Pushkal | Officer | S-Sale | D | Common Stock | 426 | 250.08 | 106.5K | 16,724 | D | ↗ |
| 2024-11-27 | Fitzgerald Kevin Joseph | Officer | S-Sale | D | Common Stock | 110 | 254.48 | 28.0K | 12,881 | D | ↗ |
| 2024-11-26 | Tanguler Tolga | Officer | S-Sale | D | Common Stock | 84 | 252.27 | 21.2K | 13,191 | D | ↗ |
| 2024-11-26 | Poulton Jeffrey V. | Officer | S-Sale | D | Common Stock | 945 | 251.42 | 237.6K | 30,741 | D | ↗ |
| 2024-11-26 | Greenstreet Yvonne | Director / Officer | S-Sale | D | Common Stock | 93 | 247.77 | 23.0K | 84,006 | D | ↗ |
| 2024-11-26 | Garg Pushkal | Officer | S-Sale | D | Common Stock | 246 | 249.60 | 61.4K | 18,863 | D | ↗ |
| 2024-11-26 | Fitzgerald Kevin Joseph | Officer | S-Sale | D | Common Stock | 318 | 250.68 | 79.7K | 15,322 | D | ↗ |
| 2024-11-25 | Tanguler Tolga | Officer | A-Award | A | Common Stock | 3,000 | 0.00 | — | 14,660 | D | ↗ |
| 2024-11-25 | Poulton Jeffrey V. | Officer | A-Award | A | Common Stock | 3,434 | 0.00 | — | 32,326 | D | ↗ |
| 2024-11-25 | Greenstreet Yvonne | Director / Officer | A-Award | A | Common Stock | 10,658 | 0.00 | — | 84,099 | D | ↗ |
| 2024-11-25 | Garg Pushkal | Officer | A-Award | A | Common Stock | 3,434 | 0.00 | — | 19,139 | D | ↗ |
| 2024-11-25 | Fitzgerald Kevin Joseph | Officer | A-Award | A | Common Stock | 3,000 | 0.00 | — | 15,881 | D | ↗ |
| 2024-10-17 | Reitan Colleen F | Director | P-Purchase | A | Common Stock | 4 | 302.67 | 1.2K | 36 | D | ↗ |
| 2024-10-08 | Garg Pushkal | Officer | A-Award | A | Common Stock | 96 | 0.00 | — | 15,705 | D | ↗ |
| 2024-10-01 | Hesslein Robert W. | Officer | A-Award | A | Common Stock | 7,245 | 0.00 | — | 7,245 | D | ↗ |
| 2024-09-30 | Hesslein Robert W. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-08-29 | Reitan Colleen F | Director | P-Purchase | A | Common Stock | 32 | 286.00 | 9.2K | 32 | D | ↗ |
| 2024-08-20 | Greenstreet Yvonne | Director / Officer | M-Exempt | A | Common Stock | 15,000 | 85.00 | 1.28M | 88,441 | — | ↗ |
| 2024-08-12 | Fitzgerald Kevin Joseph | Officer | S-Sale | D | Common Stock | 5,736 | 271.32 | 1.56M | 18,087 | — | ↗ |
| 2024-08-06 | Ausiello Dennis A | Director | M-Exempt | A | Common Stock | 9,000 | 105.26 | 947.3K | 20,386 | — | ↗ |
| 2024-08-01 | Greenstreet Yvonne | Director / Officer | S-Sale | D | Common Stock | 15,148 | 270.00 | 4.09M | 73,441 | — | ↗ |
| 2024-07-11 | Greenstreet Yvonne | Director / Officer | S-Sale | D | Common Stock | 7,093 | 261.00 | 1.85M | 73,441 | — | ↗ |
| 2024-06-25 | Tanguler Tolga | Officer | S-Sale | D | Common Stock | 129 | 228.30 | 29.5K | 13,012 | — | ↗ |
| 2024-06-25 | SCHULMAN AMY W | Director | M-Exempt | A | Common Stock | 8,500 | 131.21 | 1.12M | 16,936 | — | ↗ |
| 2024-06-25 | Poulton Jeffrey V. | Officer | S-Sale | D | Common Stock | 59 | 221.71 | 13.1K | 30,438 | — | ↗ |
| 2024-06-25 | Greenstreet Yvonne | Director / Officer | S-Sale | D | Common Stock | 957 | 234.66 | 224.6K | 81,397 | — | ↗ |
| 2024-06-25 | Garg Pushkal | Officer | S-Sale | D | Common Stock | 242 | 234.66 | 56.8K | 15,828 | — | ↗ |
| 2024-06-25 | Fitzgerald Kevin Joseph | Officer | S-Sale | D | Common Stock | 26 | 226.82 | 5.9K | 15,286 | — | ↗ |
| 2024-06-24 | Tanguler Tolga | Officer | A-Award | A | Common Stock | 3,278 | 0.00 | — | 13,265 | — | ↗ |
| 2024-06-24 | Poulton Jeffrey V. | Officer | A-Award | A | Common Stock | 3,278 | 0.00 | — | 30,497 | — | ↗ |
| 2024-06-24 | PYOTT DAVID E I | Director | M-Exempt | D | Stock Option (right to buy) | 17,560 | 88.95 | 1.56M | 7,440 | — | ↗ |
| 2024-06-24 | Greenstreet Yvonne | Director / Officer | A-Award | A | Common Stock | 16,953 | 0.00 | — | 88,835 | — | ↗ |
| 2024-06-24 | Garg Pushkal | Officer | A-Award | A | Common Stock | 4,295 | 0.00 | — | 17,712 | — | ↗ |
| 2024-06-24 | Fitzgerald Kevin Joseph | Officer | A-Award | A | Common Stock | 2,498 | 0.00 | — | 15,379 | — | ↗ |
| 2024-05-29 | SCHULMAN AMY W | Director | S-Sale | D | Common Stock | 11,516 | 148.93 | 1.72M | 8,499 | — | ↗ |
| 2024-05-16 | Sigal Charles Elliott | Director | A-Award | A | Stock Option (right to buy) | 5,228 | 151.22 | 790.6K | 5,228 | — | ↗ |
| 2024-05-16 | SHARP PHILLIP A | Director | A-Award | A | Stock Option (right to buy) | 5,228 | 151.22 | 790.6K | 5,228 | — | ↗ |
| 2024-05-16 | SCHULMAN AMY W | Director | A-Award | A | Stock Option (right to buy) | 5,228 | 151.22 | 790.6K | 5,228 | — | ↗ |
| 2024-05-16 | Reitan Colleen F | Director | A-Award | A | Stock Option (right to buy) | 5,228 | 151.22 | 790.6K | 5,228 | — | ↗ |
| 2024-05-16 | PYOTT DAVID E I | Director | A-Award | A | Stock Option (right to buy) | 5,228 | 151.22 | 790.6K | 5,228 | — | ↗ |
| 2024-05-16 | KELLOGG PETER N | Director | A-Award | A | Stock Option (right to buy) | 5,228 | 151.22 | 790.6K | 5,228 | — | ↗ |
| 2024-05-16 | HAMBURG MARGARET A | Director | A-Award | A | Stock Option (right to buy) | 5,228 | 151.22 | 790.6K | 5,228 | — | ↗ |
| 2024-05-16 | Bertozzi Carolyn R | Director | A-Award | A | Stock Option (right to buy) | 5,228 | 151.22 | 790.6K | 5,228 | — | ↗ |
| 2024-05-16 | BRANDICOURT OLIVIER | Director | A-Award | A | Stock Option (right to buy) | 5,228 | 151.22 | 790.6K | 5,228 | — | ↗ |
| 2024-05-16 | BONNEY MICHAEL W | Director | A-Award | A | Stock Option (right to buy) | 5,228 | 151.22 | 790.6K | 5,228 | — | ↗ |
| 2024-05-16 | Ausiello Dennis A | Director | A-Award | A | Stock Option (right to buy) | 5,228 | 151.22 | 790.6K | 5,228 | — | ↗ |
| 2024-03-20 | Fitzgerald Kevin Joseph | Officer | — | D | Stock Option (right to buy) | 14,580 | 118.05 | 1.72M | 0 | — | ↗ |
| 2024-03-01 | Tanguler Tolga | Officer | A-Award | A | Common Stock | 4,751 | 0.00 | — | 9,987 | — | ↗ |
| 2024-03-01 | Poulton Jeffrey V. | Officer | A-Award | A | Stock Option (right to buy) | 15,118 | 152.61 | 2.31M | 15,118 | — | ↗ |
| 2024-03-01 | Greenstreet Yvonne | Director / Officer | A-Award | A | Stock Option (right to buy) | 46,394 | 152.61 | 7.08M | 46,394 | — | ↗ |
| 2024-03-01 | Garg Pushkal | Officer | A-Award | A | Stock Option (right to buy) | 9,279 | 152.61 | 1.42M | 9,279 | — | ↗ |
| 2024-02-29 | SHARP PHILLIP A | Director | S-Sale | D | Common Stock | 915 | 152.40 | 139.4K | 2,523 | — | ↗ |
| 2024-02-28 | Tanguler Tolga | Officer | S-Sale | D | Common Stock | 216 | 154.54 | 33.4K | 5,521 | — | ↗ |
| 2024-02-28 | Poulton Jeffrey V. | Officer | S-Sale | D | Common Stock | 1 | 158.09 | 158.09 | 19,478 | — | ↗ |
| 2024-02-28 | Greenstreet Yvonne | Director / Officer | S-Sale | D | Common Stock | 588 | 156.38 | 92.0K | 48,220 | — | ↗ |
| 2024-02-28 | Garg Pushkal | Officer | S-Sale | D | Common Stock | 17 | 157.30 | 2.7K | 8,667 | — | ↗ |
| 2024-02-28 | Franchini Indrani Lall | Officer | S-Sale | D | Common Stock | 142 | 154.54 | 21.9K | 4,320 | — | ↗ |
| 2024-02-27 | Tanguler Tolga | Officer | M-Exempt | A | Common Stock | 1,667 | 0.00 | — | 5,737 | — | ↗ |
| 2024-02-27 | Poulton Jeffrey V. | Officer | M-Exempt | D | Restricted Stock Units | 1,908 | 0.00 | — | 3,816 | — | ↗ |
| 2024-02-27 | Greenstreet Yvonne | Director / Officer | M-Exempt | A | Common Stock | 5,921 | 0.00 | — | 51,060 | — | ↗ |
| 2024-02-27 | Garg Pushkal | Officer | M-Exempt | D | Restricted Stock Units | 1,908 | 0.00 | — | 3,816 | — | ↗ |
| 2024-02-27 | Franchini Indrani Lall | Officer | M-Exempt | D | Restricted Stock Units | 878 | 0.00 | — | 1,754 | — | ↗ |
| 2024-02-16 | Tanguler Tolga | Officer | S-Sale | D | Common Stock | 121 | 149.03 | 18.0K | 4,070 | — | ↗ |
| 2024-02-16 | Poulton Jeffrey V. | Officer | S-Sale | D | Common Stock | 518 | 148.24 | 76.8K | 18,264 | — | ↗ |
| 2024-02-16 | Greenstreet Yvonne | Director / Officer | S-Sale | D | Common Stock | 840 | 149.03 | 125.2K | 45,139 | — | ↗ |
| 2024-02-16 | Garg Pushkal | Officer | S-Sale | D | Common Stock | 156 | 149.03 | 23.2K | 7,332 | — | ↗ |
| 2024-02-15 | Tanguler Tolga | Officer | A-Award | A | Common Stock | 3,278 | 0.00 | — | 5,079 | — | ↗ |
| 2024-02-15 | Poulton Jeffrey V. | Officer | A-Award | A | Common Stock | 3,278 | 0.00 | — | 19,151 | — | ↗ |
| 2024-02-15 | Greenstreet Yvonne | Director / Officer | A-Award | A | Common Stock | 16,953 | 0.00 | — | 52,169 | — | ↗ |
| 2024-02-15 | Garg Pushkal | Officer | A-Award | A | Common Stock | 4,295 | 0.00 | — | 8,640 | — | ↗ |
| 2024-02-02 | Franchini Indrani Lall | Officer | S-Sale | D | Common Stock | 269 | 172.38 | 46.4K | 3,584 | — | ↗ |
| 2024-02-01 | Franchini Indrani Lall | Officer | M-Exempt | D | Restricted Stock Units | 5,175 | 0.00 | — | 5,175 | — | ↗ |
Executive team
Top executives
EBIT / Employee
224.9K
Shares Outstanding
133.43M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Yvonne L. Greenstreet, M.D. Chief Executive Officer (principal executive officer) | 1.40M | — | 5.51M | 4.36M | 3.56M | 25.0K | 14.87M | 66.43% | ↗ |
| 2 | 2025 | Jeffrey V. Poulton Executive Vice President, Chief Financial Officer (principal financial officer) | 724.4K | — | 3.99M | 1.18M | 950.3K | 22.4K | 6.86M | 75.27% | ↗ |
| 3 | 2025 | Bryan A. Supran Executive Vice President, Chief Legal Officer and Secretary | 190.4K | 350.0K | 6.00M | — | 214.8K | 90.7K | 6.85M | 87.64% | ↗ |
| 4 | 2025 | Pushkal Garg, M.D. Executive Vice President, Chief Research and Development Officer | 767.9K | — | 3.69M | 940.1K | 1.07M | 22.4K | 6.49M | 71.30% | ↗ |
| 5 | 2025 | Tolga Tanguler Executive Vice President, Chief Commercial Officer | 698.0K | — | 3.69M | 940.1K | 783.2K | 20.1K | 6.13M | 75.50% | ↗ |
| 6 | 2024 | Yvonne L. Greenstreet, M.D. Chief Executive Officer (principal executive officer) | 1.25M | — | 3.63M | 3.61M | 2.98M | 24.8K | 11.49M | 62.99% | ↗ |
| 7 | 2024 | Jeffrey V. Poulton Executive Vice President, Chief Financial Officer (principal financial officer) | 687.4K | — | 1.18M | 1.18M | 724.2K | 22.2K | 3.79M | 62.20% | ↗ |
| 8 | 2024 | Pushkal Garg, M.D. Executive Vice President, Chief Research and Development Officer | 682.1K | — | 775.2K | 722.9K | 716.9K | 22.2K | 2.92M | 51.32% | ↗ |
| 9 | 2024 | Pushkal Garg, M.D. Executive Vice President, Chief Medical Officer | 682.1K | — | 775.2K | 722.9K | 716.9K | 22.2K | 2.92M | 51.32% | ↗ |
| 10 | 2024 | Tolga Tanguler Executive Vice President, Chief Commercial Officer | 627.4K | — | 725.0K | 722.9K | 659.4K | 19.9K | 2.75M | 52.56% | ↗ |
| 11 | 2024 | Kevin J. Fitzgerald, Ph.D. Executive Vice President, Chief Scientific Officer | 586.6K | — | 725.0K | 722.9K | 616.6K | 22.2K | 2.67M | 54.16% | ↗ |
| 12 | 2023 | Yvonne L. Greenstreet, MBChB, MBA Chief Executive Officer (principal executive officer) | 975.8K | — | 3.38M | 3.37M | 1.16M | 20.7K | 8.90M | 75.81% | ↗ |
| 13 | 2023 | Yvonne L. Greenstreet, M.D. Chief Executive Officer (principal executive officer) | 975.8K | — | 3.38M | 3.37M | 1.16M | 20.7K | 8.90M | 75.81% | ↗ |
| 14 | 2023 | Akshay K. Vaishnaw, M.D., Ph.D. Former President | 647.8K | — | 1.10M | 1.10M | 450.5K | 20.7K | 3.32M | 66.27% | ↗ |
| 15 | 2023 | Pushkal Garg, M.D. Executive Vice President, Chief Medical Officer | 656.9K | — | 1.09M | 1.09M | 382.9K | 18.1K | 3.23M | 67.26% | ↗ |
| 16 | 2023 | Pushkal Garg, M.D. Executive Vice President, Chief Research and Development Officer | 656.9K | — | 1.09M | 1.09M | 382.9K | 18.1K | 3.23M | 67.26% | ↗ |
| 17 | 2023 | Jeffrey V. Poulton Executive Vice President, Chief Financial Officer (principal financial officer) | 651.9K | — | 1.09M | 1.09M | 381.2K | 18.1K | 3.22M | 67.40% | ↗ |
| 18 | 2023 | Tolga Tanguler Executive Vice President, Chief Commercial Officer | 603.2K | — | 950.1K | 948.4K | 352.3K | 15.8K | 2.87M | 66.15% | ↗ |
| 19 | 2023 | Kevin J. Fitzgerald, Ph.D. Executive Vice President, Chief Scientific Officer | 539.6K | — | 950.1K | 948.4K | 329.2K | 18.0K | 2.79M | 68.16% | ↗ |
| 20 | 2023 | Indrani L. Franchini, J.D. Executive Vice President, Chief Legal Officer | 594.3K | — | 500.1K | 499.2K | 344.8K | 31.6K | 1.97M | 50.73% | ↗ |
| 21 | 2022 | Indrani L. Franchini, J.D. Executive Vice President, Chief Legal Officer and Secretary | 535.4K | — | 2.25M | 2.25M | 333.5K | 41.3K | 5.41M | 83.17% | ↗ |
| 22 | 2022 | Indrani L. Franchini, J.D. Executive Vice President, Chief Legal Officer | 535.4K | — | 2.25M | 2.25M | 333.5K | 41.3K | 5.41M | 83.17% | ↗ |
| 23 | 2022 | Yvonne L. Greenstreet, MBChB, MBA Chief Executive Officer (principal executive officer) | 850.0K | — | — | 2.50M | 977.5K | 262.5K | 4.59M | 54.45% | ↗ |
| 24 | 2022 | Yvonne L. Greenstreet, M.D. Chief Executive Officer (principal executive officer) | 850.0K | — | — | 2.50M | 977.5K | 262.5K | 4.59M | 54.45% | ↗ |
| 25 | 2022 | Akshay K. Vaishnaw, M.D., Ph.D. Former President | 725.0K | — | — | 2.35M | 500.3K | 17.5K | 3.59M | 65.40% | ↗ |
| 26 | 2022 | Akshay K. Vaishnaw, M.D., Ph.D. President | 725.0K | — | — | 2.35M | 500.3K | 17.5K | 3.59M | 65.40% | ↗ |
| 27 | 2022 | Pushkal P. Garg, M.D. Chief Medical Officer and Executive Vice President, Development Medical Affairs | 625.0K | — | — | 1.90M | 359.4K | 17.1K | 2.90M | 65.47% | ↗ |
| 28 | 2022 | Pushkal Garg, M.D. Executive Vice President, Chief Medical Officer | 625.0K | — | — | 1.90M | 359.4K | 17.1K | 2.90M | 65.47% | ↗ |
| 29 | 2022 | Kevin J. Fitzgerald, Ph.D. Executive Vice President, Chief Scientific Officer | 493.7K | — | — | 1.60M | 330.6K | 17.1K | 2.45M | 65.60% | ↗ |
| 30 | 2022 | Jeffrey V. Poulton Executive Vice President, Chief Financial Officer (principal financial officer) | 604.5K | — | — | 1.45M | 350.8K | 17.1K | 2.42M | 59.85% | ↗ |
| 31 | 2022 | Tolga Tanguler Executive Vice President, Chief Commercial Officer | 564.8K | — | — | 1.45M | 326.4K | 11.6K | 2.35M | 61.62% | ↗ |
| 32 | 2021 | John M. Maraganore, Ph.D. Former Chief Executive Officer (principal executive officer) | 948.5K | — | — | 7.86M | 1.10M | 271.1K | 10.18M | 77.25% | ↗ |
| 33 | 2021 | Yvonne L. Greenstreet, MBChB, MBA President and Chief Operating Officer | 619.1K | — | — | 7.34M | 429.1K | 186.0K | 8.58M | 85.61% | ↗ |
| 34 | 2021 | Yvonne L. Greenstreet, MBChB, MBA Chief Executive Officer (principal executive officer) | 619.1K | — | — | 7.34M | 429.1K | 186.0K | 8.58M | 85.61% | ↗ |
| 35 | 2021 | Tolga Tanguler Executive Vice President, Chief Commercial Officer | 547.9K | — | 1.50M | 4.50M | 316.3K | 11.7K | 6.88M | 87.26% | ↗ |
| 36 | 2021 | Akshay K. Vaishnaw, M.D., Ph.D. President, Research and Development | 632.2K | — | — | 4.34M | 438.2K | 14.9K | 5.43M | 80.00% | ↗ |
| 37 | 2021 | Akshay K. Vaishnaw, M.D., Ph.D. Former President | 632.2K | — | — | 4.34M | 438.2K | 14.9K | 5.43M | 80.00% | ↗ |
| 38 | 2021 | Akshay K. Vaishnaw, M.D., Ph.D. President | 632.2K | — | — | 4.34M | 438.2K | 14.9K | 5.43M | 80.00% | ↗ |
| 39 | 2021 | Pushkal Garg, M.D. Executive Vice President, Chief Medical Officer | 568.9K | — | — | 3.08M | 380.2K | 14.2K | 4.05M | 76.20% | ↗ |
| 40 | 2021 | Pushkal P. Garg, M.D. Chief Medical Officer and Executive Vice President, Development Medical Affairs | 568.9K | — | — | 3.08M | 380.2K | 14.2K | 4.05M | 76.20% | ↗ |
| 41 | 2021 | Jeffrey V. Poulton Executive Vice President, Chief Financial Officer (principal financial officer) | 569.2K | — | — | 1.88M | 330.6K | 14.2K | 2.80M | 67.33% | ↗ |
| 42 | 2020 | Barry E. Greene Former President | 484.0K | — | 457.6K | 8.31M | 376.4K | 717.3K | 10.35M | 84.75% | ↗ |
| 43 | 2020 | John M. Maraganore, Ph.D. Former Chief Executive Officer (principal executive officer) | 946.2K | — | — | 5.75M | 1.11M | 15.7K | 7.82M | 73.50% | ↗ |
| 44 | 2020 | John M. Maraganore, Ph.D. Chief Executive Officer (principal executive officer) | 946.2K | — | — | 5.75M | 1.11M | 15.7K | 7.82M | 73.50% | ↗ |
| 45 | 2020 | Yvonne L. Greenstreet, MBChB, MBA President and Chief Operating Officer | 621.5K | — | — | 1.80M | 434.7K | 178.9K | 3.03M | 59.29% | ↗ |
| 46 | 2020 | Yvonne L. Greenstreet, MBChB, MBA Chief Executive Officer (principal executive officer) | 621.5K | — | — | 1.80M | 434.7K | 178.9K | 3.03M | 59.29% | ↗ |
| 47 | 2020 | Akshay K. Vaishnaw, M.D., Ph.D. President | 634.6K | — | — | 1.80M | 443.9K | 14.9K | 2.89M | 62.20% | ↗ |
| 48 | 2020 | Akshay K. Vaishnaw, M.D., Ph.D. President, Research and Development | 634.6K | — | — | 1.80M | 443.9K | 14.9K | 2.89M | 62.20% | ↗ |
| 49 | 2020 | Pushkal P. Garg, M.D. Chief Medical Officer and Executive Vice President, Development Medical Affairs | 553.2K | — | — | 1.70M | 321.4K | 14.2K | 2.59M | 65.65% | ↗ |
| 50 | 2020 | Jeffrey V. Poulton Executive Vice President, Chief Financial Officer (principal financial officer) | 556.8K | — | — | 1.60M | 322.6K | 14.6K | 2.49M | 64.14% | ↗ |
| 51 | 2020 | Laurie B. Keating Executive Vice President, Chief Legal Officer and Secretary | 544.6K | — | — | 1.60M | 265.0K | 25.6K | 2.43M | 65.69% | ↗ |
| 52 | 2019 | John M. Maraganore, Ph.D. Chief Executive Officer (principal executive officer) | 845.0K | — | 1.20M | 4.33M | 913.8K | 27.8K | 7.32M | 75.59% | ↗ |
| 53 | 2019 | John M. Maraganore, Ph.D. Former Chief Executive Officer (principal executive officer) | 845.0K | — | 1.20M | 4.33M | 913.8K | 27.8K | 7.32M | 75.59% | ↗ |
| 54 | 2019 | Jeffrey V. Poulton Executive Vice President, Chief Financial Officer (principal financial officer) | 254.8K | — | — | 5.48M | 136.7K | 6.3K | 5.88M | 93.23% | ↗ |
| 55 | 2019 | Manmeet S. Soni Former Senior Vice President, Chief Financial Officer (former principal financial officer) | 314.4K | — | 283.4K | 2.02M | — | 694.5K | 3.31M | 69.51% | ↗ |
| 56 | 2019 | Yvonne L. Greenstreet, MBChB, MBA Chief Operating Officer | 571.4K | — | 460.4K | 1.65M | 370.9K | 192.9K | 3.25M | 65.07% | ↗ |
| 57 | 2019 | Yvonne L. Greenstreet, MBChB, MBA President and Chief Operating Officer | 571.4K | — | 460.4K | 1.65M | 370.9K | 192.9K | 3.25M | 65.07% | ↗ |
| 58 | 2019 | Barry E. Greene Former President | 596.8K | — | 460.4K | 1.65M | 385.3K | 21.4K | 3.12M | 67.82% | ↗ |
| 59 | 2019 | Barry E. Greene President | 596.8K | — | 460.4K | 1.65M | 385.3K | 21.4K | 3.12M | 67.82% | ↗ |
| 60 | 2019 | Akshay K. Vaishnaw, M.D., Ph.D. President, Research and Development | 586.5K | — | 460.4K | 1.65M | 378.7K | 20.9K | 3.10M | 68.20% | ↗ |
| 61 | 2019 | Laurie B. Keating Executive Vice President, Chief Legal Officer and Secretary | 490.4K | — | 354.1K | 1.27M | 268.8K | 35.7K | 2.42M | 67.18% | ↗ |
| 62 | 2018 | John M. Maraganore, Ph.D. Chief Executive Officer (principal executive officer) | 800.0K | — | — | 3.78M | 480.0K | 27.0K | 5.09M | 74.32% | ↗ |
| 63 | 2018 | Barry E. Greene President | 580.0K | — | — | 2.16M | 232.0K | 21.1K | 2.99M | 72.18% | ↗ |
| 64 | 2018 | Barry E. Greene Former President | 580.0K | — | — | 2.16M | 232.0K | 21.1K | 2.99M | 72.18% | ↗ |
| 65 | 2018 | Yvonne L. Greenstreet, MBChB, MBA President and Chief Operating Officer | 540.0K | — | — | 1.80M | 216.0K | 125.7K | 2.68M | 67.13% | ↗ |
| 66 | 2018 | Yvonne L. Greenstreet, MBChB, MBA Chief Operating Officer | 540.0K | — | — | 1.80M | 216.0K | 125.7K | 2.68M | 67.13% | ↗ |
| 67 | 2018 | Akshay K. Vaishnaw, M.D., Ph.D. President, Research and Development | 570.0K | — | — | 1.80M | 228.0K | 20.6K | 2.62M | 68.75% | ↗ |
| 68 | 2018 | Laurie B. Keating Executive Vice President, Chief Legal Officer and Secretary | 446.7K | — | — | 990.6K | 144.0K | 32.7K | 1.61M | 61.37% | ↗ |
| 69 | 2018 | Manmeet S. Soni Senior Vice President, Chief Financial Officer (principal financial officer) | 500.0K | 50.0K | — | 643.9K | 160.0K | 9.8K | 1.36M | 47.22% | ↗ |
| 70 | 2018 | Manmeet S. Soni Former Senior Vice President, Chief Financial Officer (former principal financial officer) | 500.0K | 50.0K | — | 643.9K | 160.0K | 9.8K | 1.36M | 47.22% | ↗ |
| 71 | 2017 | Manmeet S. Soni Former Senior Vice President, Chief Financial Officer (former principal financial officer) | 318.5K | 100.0K | — | 3.85M | 165.6K | 44.2K | 4.48M | 85.98% | ↗ |
| 72 | 2017 | Manmeet S. Soni Senior Vice President, Chief Financial Officer (principal financial officer) | 318.5K | 100.0K | — | 3.85M | 165.6K | 44.2K | 4.48M | 85.98% | ↗ |
| 73 | 2017 | John M. Maraganore, Ph.D. Chief Executive Officer (principal executive officer) | 753.5K | — | — | — | 636.7K | 27.1K | 1.42M | 0.00% | ↗ |
| 74 | 2017 | Yvonne L. Greenstreet, MBChB, MBA Executive Vice President, Chief Operating Officer | 504.2K | — | — | — | 327.7K | 152.7K | 984.7K | 0.00% | ↗ |
| 75 | 2017 | Yvonne L. Greenstreet, MBChB, MBA Chief Operating Officer | 504.2K | — | — | — | 327.7K | 152.7K | 984.7K | 0.00% | ↗ |
| 76 | 2017 | Barry E. Greene President | 562.8K | — | — | — | 365.8K | 15.5K | 944.1K | 0.00% | ↗ |
| 77 | 2017 | Akshay K. Vaishnaw, M.D., Ph.D. President, Research and Development | 542.1K | — | — | — | 352.4K | 20.7K | 915.2K | 0.00% | ↗ |
| 78 | 2017 | Michael P. Mason Vice President of Finance and Treasurer (former principal financial officer) | 318.3K | — | — | — | 124.1K | 8.9K | 451.4K | 0.00% | ↗ |
| 79 | 2017 | David-Alexandre C. Gros, M.D. Former Senior Vice President, Chief Business Officer (former principal financial officer) | 8.3K | — | — | — | — | 8.5K | 16.9K | 0.00% | ↗ |
| 80 | 2016 | Yvonne L. Greenstreet, MBChB Executive Vice President, Chief Operating Officer | 144.2K | 100.0K | — | 5.65M | 56.0K | 40.4K | 5.99M | 94.31% | ↗ |
| 81 | 2016 | Yvonne L. Greenstreet, MBChB, MBA Chief Operating Officer | 144.2K | 100.0K | — | 5.65M | 56.0K | 40.4K | 5.99M | 94.31% | ↗ |
| 82 | 2016 | Yvonne L. Greenstreet, MBChB, MBA Executive Vice President, Chief Operating Officer | 144.2K | 100.0K | — | 5.65M | 56.0K | 40.4K | 5.99M | 94.31% | ↗ |
| 83 | 2016 | John M. Maraganore, Ph.D. Chief Executive Officer (principal executive officer) | 731.6K | — | — | 621.0K | 380.4K | 11.9K | 1.74M | 35.59% | ↗ |
| 84 | 2016 | Akshay K. Vaishnaw, M.D., Ph.D. President, Research and Development | 526.4K | — | — | 787.8K | 210.5K | 10.1K | 1.53M | 51.33% | ↗ |
| 85 | 2016 | Akshay K. Vaishnaw, M.D., Ph.D. E xecutive Vice President, Research and Development | 526.4K | — | — | 787.8K | 210.5K | 10.1K | 1.53M | 51.33% | ↗ |
| 86 | 2016 | Barry E. Greene President | 546.4K | — | — | 621.0K | 218.6K | 10.2K | 1.40M | 44.48% | ↗ |
| 87 | 2016 | David-Alexandre C. Gros, M.D. Former Senior Vice President, Chief Business Officer (former principal financial officer) | 432.3K | 100.0K | — | 621.0K | 138.3K | 1.6K | 1.29M | 48.02% | ↗ |
| 88 | 2016 | Michael P. Mason Vice President of Finance and Treasurer (former principal financial officer) | 309.1K | — | 318.3K | 137.9K | 74.2K | 6.7K | 846.1K | 53.91% | ↗ |
| 89 | 2016 | Michael P. Mason Vice President of Finance and Treasurer (principal financial officer) | 309.1K | — | 318.3K | 137.9K | 74.2K | 6.7K | 846.1K | 53.91% | ↗ |
| 90 | 2015 | David-Alexandre C. Gros, M.D. Senior Vice President, Chief Business Officer | 241.1K | 200.0K | — | 9.63M | 95.8K | 508.00 | 10.17M | 94.71% | ↗ |
| 91 | 2015 | David-Alexandre C. Gros, M.D. Former Senior Vice President, Chief Business Officer (former principal financial officer) | 241.1K | 200.0K | — | 9.63M | 95.8K | 508.00 | 10.17M | 94.71% | ↗ |
| 92 | 2015 | John M. Maraganore, Ph.D. Chief Executive Officer (principal executive officer) | 710.3K | — | — | 7.12M | 419.8K | 7.6K | 8.26M | 86.23% | ↗ |
| 93 | 2015 | Barry E. Greene President | 530.5K | — | — | 4.47M | 261.2K | 7.9K | 5.26M | 84.81% | ↗ |
| 94 | 2015 | Barry E. Greene President and Chief Operating Officer | 530.5K | — | — | 4.47M | 261.2K | 7.9K | 5.26M | 84.81% | ↗ |
| 95 | 2015 | Akshay K. Vaishnaw, M.D., Ph.D. Executive Vice President, Research and Development and Chief Medical Officer | 500.1K | — | — | 3.32M | 251.7K | 7.6K | 4.08M | 81.37% | ↗ |
| 96 | 2015 | Akshay K. Vaishnaw, M.D., Ph.D. President, Research and Development | 500.1K | — | — | 3.32M | 251.7K | 7.6K | 4.08M | 81.37% | ↗ |
| 97 | 2015 | Akshay K. Vaishnaw, M.D., Ph.D. E xecutive Vice President, Research and Development | 500.1K | — | — | 3.32M | 251.7K | 7.6K | 4.08M | 81.37% | ↗ |
| 98 | 2015 | Michael P. Mason Vice President of Finance and Treasurer (principal financial officer) | 300.0K | — | — | 1.21M | 88.7K | 6.3K | 1.61M | 75.41% | ↗ |
| 99 | 2015 | Michael P. Mason Vice President of Finance and Treasurer (former principal financial officer) | 300.0K | — | — | 1.21M | 88.7K | 6.3K | 1.61M | 75.41% | ↗ |
| 100 | 2014 | Laurie B. Keating Senior Vice President, General Counsel and Secretary | 110.8K | 100.0K | — | 5.04M | 57.0K | 1.7K | 5.31M | 94.92% | ↗ |
| 101 | 2014 | John M. Maraganore, Ph.D. Chief Executive Officer (principal executive officer) | 689.6K | — | — | — | 444.0K | 7.6K | 1.14M | 0.00% | ↗ |
| 102 | 2014 | Barry E. Greene President | 515.0K | — | — | — | 276.0K | 8.0K | 799.0K | 0.00% | ↗ |
| 103 | 2014 | Barry E. Greene President and Chief Operating Officer | 515.0K | — | — | — | 276.0K | 8.0K | 799.0K | 0.00% | ↗ |
| 104 | 2014 | Akshay K. Vaishnaw, M.D., Ph.D. Executive Vice President, Research and Development and Chief Medical Officer | 463.5K | — | — | — | 249.0K | 7.6K | 720.1K | 0.00% | ↗ |
| 105 | 2014 | Akshay K. Vaishnaw, M.D., Ph.D. E xecutive Vice President, Research and Development | 463.5K | — | — | — | 249.0K | 7.6K | 720.1K | 0.00% | ↗ |
| 106 | 2014 | Michael P. Mason Vice President of Finance and Treasurer (principal financial officer) | 257.2K | — | — | — | 82.0K | 6.2K | 345.4K | 0.00% | ↗ |
| 107 | 2013 | John M. Maraganore, Ph.D. Chief Executive Officer (principal executive officer) | 669.5K | — | — | 5.13M | 431.8K | 7.6K | 6.24M | 82.22% | ↗ |
| 108 | 2013 | Barry E. Greene President and Chief Operating Officer | 500.0K | — | — | 3.21M | 268.8K | 7.7K | 3.98M | 80.51% | ↗ |
| 109 | 2013 | Akshay K. Vaishnaw, M.D., Ph.D. Executive Vice President, Research and Development and Chief Medical Officer | 450.0K | — | — | 1.05M | 241.9K | 7.6K | 1.75M | 59.98% | ↗ |
| 110 | 2013 | Akshay K. Vaishnaw, M.D., Ph.D. Executive Vice President and Chief Medical Officer | 450.0K | — | — | 1.05M | 241.9K | 7.6K | 1.75M | 59.98% | ↗ |
| 111 | 2013 | Laurence E. Reid, Ph.D. Senior Vice President and Chief Business Officer | 375.0K | 25.0K | — | 645.2K | 161.3K | 7.2K | 1.21M | 53.16% | ↗ |
| 112 | 2013 | Michael P. Mason Vice President of Finance and Treasurer (principal financial officer) | 252.1K | — | — | 161.3K | 81.3K | 6.1K | 500.9K | 32.20% | ↗ |
| 113 | 2012 | John M. Maraganore, Ph.D. Chief Executive Officer (principal executive officer) | 669.5K | — | — | 1.42M | 313.3K | 8.8K | 2.42M | 58.96% | ↗ |
| 114 | 2012 | Barry E. Greene President and Chief Operating Officer | 475.0K | — | — | 949.6K | 195.0K | 20.7K | 1.64M | 57.89% | ↗ |
| 115 | 2012 | Akshay K. Vaishnaw, M.D., Ph.D. Executive Vice President, Research and Development and Chief Medical Officer | 423.3K | — | 132.2K | 474.8K | 175.5K | 6.4K | 1.21M | 50.07% | ↗ |
| 116 | 2012 | Akshay K. Vaishnaw, M.D., Ph.D. Executive Vice President and Chief Medical Officer | 423.3K | — | 132.2K | 474.8K | 175.5K | 6.4K | 1.21M | 50.07% | ↗ |
| 117 | 2012 | Laurence E. Reid, Ph.D. Senior Vice President and Chief Business Officer | 338.7K | 25.0K | 112.9K | 379.8K | 105.7K | 5.9K | 967.9K | 50.91% | ↗ |
| 118 | 2012 | Michael P. Mason Vice President of Finance and Treasurer (principal financial officer) | 247.2K | — | 82.4K | 95.0K | 57.8K | 6.2K | 488.6K | 36.30% | ↗ |
| 119 | 2011 | John M. Maraganore, Ph.D. Chief Executive Officer (principal executive officer) | 595.1K | — | — | 561.3K | 229.9K | 11.9K | 1.40M | 40.15% | ↗ |
| 120 | 2011 | Akshay K. Vaishnaw, M.D., Ph.D. Executive Vice President and Chief Medical Officer | 373.9K | — | — | 637.8K | 105.1K | 6.5K | 1.12M | 56.78% | ↗ |
| 121 | 2011 | Barry E. Greene President and Chief Operating Officer | 436.8K | — | — | 374.2K | 128.7K | 12.7K | 952.5K | 39.29% | ↗ |
| 122 | 2011 | Laurence E. Reid, Ph.D. Senior Vice President and Chief Business Officer | 328.8K | 25.0K | — | 149.7K | 64.8K | 5.9K | 574.2K | 26.07% | ↗ |
| 123 | 2011 | Michael P. Mason Vice President of Finance and Treasurer (principal financial officer) | 238.1K | — | — | 202.7K | 43.7K | 6.2K | 490.6K | 41.31% | ↗ |
| 124 | 2005 | John M. Maraganore, Ph.D. President and Chief Executive Officer | 370.0K | — | — | — | — | — | 370.0K | 0.00% | ↗ |
| 125 | 2005 | Vincent J. Miles, Ph.D. Senior Vice President, Business Development | 241.9K | 84.4K | — | — | — | — | 326.3K | 0.00% | ↗ |
| 126 | 2005 | Barry E. Greene Chief Operating Officer | 265.2K | 15.0K | — | — | — | — | 280.2K | 0.00% | ↗ |
| 127 | 2004 | John M. Maraganore, Ph.D. President and Chief Executive Officer | 370.0K | — | — | — | — | — | 370.0K | 0.00% | ↗ |
| 128 | 2004 | Thomas R. Ulich, M.D. Former Senior Vice President, Research | 183.0K | — | — | — | — | 130.7K | 313.7K | 0.00% | ↗ |
| 129 | 2004 | Vincent J. Miles, Ph.D. Senior Vice President, Business Development | 237.1K | 44.5K | — | — | — | — | 281.6K | 0.00% | ↗ |
| 130 | 2004 | Vincent J. Miles, Ph.D. Senior Vice President, Business | 237.1K | 44.5K | — | — | — | — | 281.6K | 0.00% | ↗ |
| 131 | 2004 | Barry E. Greene Chief Operating Officer and Treasurer | 260.0K | — | — | — | — | — | 260.0K | 0.00% | ↗ |
| 132 | 2004 | Barry E. Greene Chief Operating Officer | 260.0K | — | — | — | — | — | 260.0K | 0.00% | ↗ |
| 133 | 2004 | John G. Conley Former Chief Financial Officer and Vice | 21.7K | — | — | — | — | 130.0K | 151.7K | 0.00% | ↗ |
| 134 | 2003 | John M. Maraganore, Ph.D. President and Chief Executive Officer | 369.4K | 110.0K | — | — | — | — | 479.4K | 0.00% | ↗ |
| 135 | 2003 | John G. Conley Former Chief Financial Officer and Vice | 259.5K | 55.3K | — | — | — | — | 314.7K | 0.00% | ↗ |
| 136 | 2003 | Thomas R. Ulich, M.D. Former Senior Vice President, Research | 157.4K | 46.1K | — | — | — | 43.5K | 247.0K | 0.00% | ↗ |
| 137 | 2003 | Vincent J. Miles, Ph.D. Senior Vice President, Business Development | 107.7K | 45.0K | — | — | — | — | 152.7K | 0.00% | ↗ |
| 138 | 2003 | Vincent J. Miles, Ph.D. Senior Vice President, Business | 107.7K | 45.0K | — | — | — | — | 152.7K | 0.00% | ↗ |
| 139 | 2003 | Barry E. Greene Chief Operating Officer | 53.3K | 58.8K | — | — | — | — | 112.1K | 0.00% | ↗ |
| 140 | 2003 | Barry E. Greene Chief Operating Officer and Treasurer | 53.3K | 58.8K | — | — | — | — | 112.1K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yvonne L. Greenstreet | Chief Executive Officer & Director | 5M | — |
| Pushkal Garg | Executive VP & Chief Research & Development Officer | 2M | — |
| Jeffrey V. Poulton | Chief Financial Officer & Executive Vice President | 2M | male |
| Tolga Tanguler | Executive Vice President & Chief Commercial Officer | 2M | male |
| Kevin Joseph Fitzgerald | Executive Vice President, Chief Scientific Officer and Head of Early Research & Early Development | 1M | — |
| Bryan Andrew Supran | Chief Legal Officer | 845.9K | male |
| Phillip A. Sharp | Co-Founder, Member of the Scientific Advisory Board | 52.9K | — |
| Piyush Sharma | Chief Ethics & Compliance Officer | — | male |
| Muthiah Manoharan | Senior Vice President of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Board | — | — |
| Timothy J. Maines | Chief Technical Operations & Quality Officer | — | male |
| Melissa McLaughlin | Chief Human Resources Officer | — | female |
| Christine Regan Akinc | Chief Corporate Communications Officer | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Political Trading Activity (25M)
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2025-05-12 | 2025-06-23 | Jefferson Shreve | IN06 | — | Sale | $15,001 - $50,000 | ↗ |
| 2024-01-29 | 2024-02-15 | Josh Gottheimer | NJ05 | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2024-01-11 | 2024-02-15 | Josh Gottheimer | NJ05 | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2023-12-11 | 2024-01-07 | Josh Gottheimer | NJ05 | Joint | Sale | $1,001 - $15,000 | ↗ |
| 2023-03-06 | 2023-04-17 | Daniel Goldman | NY10 | — | Purchase | $15,001 - $50,000 | ↗ |
| 2023-02-10 | 2023-03-08 | Ro Khanna | CA17 | Spouse | Sale | $1,001 - $15,000 | ↗ |
| 2023-01-31 | 2023-02-24 | Daniel Goldman | NY10 | — | Sale | $15,001 - $50,000 | ↗ |
| 2022-12-06 | 2023-01-03 | Ro Khanna | CA17 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2022-09-28 | 2022-10-16 | Josh Gottheimer | NJ05 | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2020-11-13 | 2020-12-09 | Josh Gottheimer | NJ05 | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2020-04-06 | 2020-05-13 | Josh Gottheimer | NJ05 | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2018-10-18 | 2018-11-16 | Josh Gottheimer | NJ05 | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2018-06-01 | 2018-10-02 | Josh Gottheimer | NJ05 | — | Purchase | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALNY
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
